Purdue University

Purdue e-Pubs
Open Access Dissertations

Theses and Dissertations

8-2018

Regulation of the Endogenous Antioxidant Defense System in
Diabetic Peripheral Neuropathy
Mateusz A. Stochelski
Purdue University

Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations

Recommended Citation
Stochelski, Mateusz A., "Regulation of the Endogenous Antioxidant Defense System in Diabetic Peripheral
Neuropathy" (2018). Open Access Dissertations. 2077.
https://docs.lib.purdue.edu/open_access_dissertations/2077

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries.
Please contact epubs@purdue.edu for additional information.

REGULATION OF THE ENDOGENOUS ANTIOXIDANT DEFENSE
SYSTEM IN DIABETIC PERIPHERAL NEUROPATHY
by
Mateusz A. Stochelski
A Dissertation
Submitted to the Faculty of Purdue University
In Partial Fulfillment of the Requirements for the degree of

Doctor of Philosophy

Department of Nutrition Science
West Lafayette, Indiana
August 2018

ii

THE PURDUE UNIVERSITY GRADUATE SCHOOL
STATEMENT OF COMMITTEE APPROVAL

Dr. John Burgess, Chair
Department of Nutrition Science
Dr. Edward L. Bartlett
Department of Biomedical Engineering
Dr. Ignacio Camarillo
Department of Biological Sciences
Dr. Kee-Hong Kim
Department of Food Science

Approved by:
Dr. Michelle R. Forman
Head of the Graduate Program

iii

For my wife Jan and our beloved pup Mia

iv

ACKNOWLEDGMENTS

Completion of this dissertation would not have been possible without the love and
support of my wife. She stood by my side each and every day of my graduate career and helped
me with statistics and SAS programming, editing manuscripts, preparing for presentations, and
was my “go-to” person for any and every technical problem I ran into. Words can only begin to
describe the amount of gratitude I have for all her love, time, and effort that made this work
possible. I would also like to thank my parents for their unwavering love and support throughout
all of these years. Visiting them in Chicago provided much needed relief from all the various
stresses of graduate life, and I am forever grateful for the loving and welcoming environment
they provided and continue to provide for Jan and me. Our pup, Mia, also deserves a heartfelt
thank you. She sat by my side, usually begging for walks or pets, through all hours of the day
and night as I worked to complete this dissertation. Her companionship is priceless, but I will do
my best to return the favor with many tasty snacks and walks in the coming days.
Further gratitude goes out to my mentor, Dr. Jay Burgess. I have worked with Dr.
Burgess since my time as an undergraduate at Purdue, and I have wondered many times
how/why I was so fortunate. Finding a better mentor is not possible. Dr. Burgess taught me most
everything I know about scientific research, from experimental design to lab techniques and data
analysis. His scientific integrity and attention to detail have left a lifelong impact on me and set
the standard for quality research. Furthermore, Dr. Burgess has taught me that mentorship goes
beyond the work environment and requires understanding of your colleagues on a “human” level.
This is something sorely missing in academia, and in my opinion is largely responsible for the
mental health issues seen in graduate students. The beginning of my graduate career was marred
by multiple health complications due to a flu virus that resulted in heart failure. This was a very

v
difficult time in my life and succeeding in academia without someone like Dr. Burgess would not
have been possible. The support that Jan and I had from Dr. Burgess, his wife, and Laura Stevens
made us feel like we had a family and support system here in Lafayette. Simply put, I would not
be where I am today without their support. I only wish I could do more to acknowledge the effort
and mentorship Dr. Burgess puts in for his students. Academia needs more people like him, and
these people need to be rewarded for their lifelong commitment to higher education.
Last, but certainly not least, I owe a debt of gratitude to the Burgess lab members. To
start, my compatriot Tomasz Wilmanski. Your suggestions, input, ideas, knowledge base, and
assistance with manuscripts helped shape the direction of this dissertation. Our friendship,
without question, helped me get through graduate school. I would also like to thank Mitchell
Walters, who was by far my most helpful undergraduate research assistant. All the meticulous
work he did analyzing GSH concentrations is well represented in this dissertation and does not
go unappreciated. Further thanks go out to Carrie Terwilliger, the newest Burgess lab member. I
appreciate all of your help and support these past few months as I have been writing this
dissertation. We have a similar approach to teaching and working as a team, and I look forward
to passing on the glutathione reductase paradox to you.

vi

TABLE OF CONTENTS

LIST OF FIGURES ........................................................................................................................ x
LIST OF ABBREVIATIONS...................................................................................................... xiii
ABSTRACT................................................................................................................................ xvii
LITERATURE REVIEW ..................................................................................... 1
1.1

Introduction......................................................................................................................... 1

1.2

Overview of the Prevalence of Diabetes and Complications.............................................. 2

1.3

Complications Due to Poor Glycemic Control ................................................................... 2

1.3.1

Cardiovascular Complications..................................................................................... 2

1.3.2

Diabetic Retinopathy ................................................................................................... 3

1.3.3

Diabetic Nephropathy.................................................................................................. 4

1.3.4

Diabetic Neuropathy.................................................................................................... 5

1.4

Overview of Oxidative Stress and its Molecular Targets ................................................... 6

1.4.1

Oxidative Stress ........................................................................................................... 6

1.4.2

Lipid Peroxidation ....................................................................................................... 6

1.4.3

DNA Oxidation............................................................................................................ 7

1.4.4

Protein Oxidation......................................................................................................... 7

1.5

Peripheral Neurons and Hyperglycemia ............................................................................. 8

1.6

Four Major Sources of ROS Generation in Diabetic Peripheral Neuropathy................... 10

1.6.1

Polyol Pathway .......................................................................................................... 10

1.6.2

PKC Pathway............................................................................................................. 13

1.6.3

Mitochondrial Pathway.............................................................................................. 17

1.6.4

AGE Pathway ............................................................................................................ 20

1.6.5

Summary of ROS Generating Pathways.................................................................... 24

1.7

Potential Therapeutic Antioxidants................................................................................... 25

1.7.1

Lipoic Acid ................................................................................................................ 25

1.7.2

Resveratrol................................................................................................................. 26

1.7.3

3H-1,2-dithiole-3-thione (D3T)-Upregulation of the endogenous antioxidant defense

system 27
1.7.4

N-acetylcysteine (NAC) ............................................................................................ 30

vii
1.8

Research Questions........................................................................................................... 32

1.9

References......................................................................................................................... 34
N-ACETYLCYSTEINE CONFERS PROTECTION AGAINST ADVANCED

GLYCATION END-PRODUCT INDUCED NEURITE RETRACTION OF SH-SY5Y CELLS
VIA A GLUTATHIONE-DEPENDENT MANNER ................................................................... 54
2.1

Abstract ............................................................................................................................. 54

2.2

Introduction....................................................................................................................... 55

2.3

Methods............................................................................................................................. 57

2.3.1

Materials .................................................................................................................... 57

2.3.2

Cell Culture................................................................................................................ 57

2.3.3

Preparation of AGE-BSA and BSA Control ............................................................. 58

2.3.4

GSH Assay................................................................................................................. 58

2.3.5

Cell Viability ............................................................................................................. 59

2.3.6

Neurite Quantification ............................................................................................... 59

2.3.7

Statistical Methods..................................................................................................... 60

2.4

Results ............................................................................................................................... 60

2.4.1

Impact of NAC on GSH Concentrations ................................................................... 60

2.4.2

The Effect of 1 mM NAC on Protection Against AGE-Induced Neurite Loss ......... 61

2.4.3

BSO Does Response for Depletion of Intracellular GSH.......................................... 61

2.4.4

The Effect of BSO Treatment on Control SH-SY5Y Cells ....................................... 62

2.4.5

The Effect of BSO Treatment on AGE-treated SH-SY5Y Cells ............................... 62

2.5

Discussion ......................................................................................................................... 63

2.6

References......................................................................................................................... 82
D3T POTENTIATES ADVANCED GLYCATION END PRODUCT

INDUCED OXIDATIVE STRESS IN A CELL CULTURE MODEL OF DIABETIC
PERIPHERAL NEUROPATHY .................................................................................................. 89
3.1

Abstract ............................................................................................................................. 89

3.2

Introduction....................................................................................................................... 90

3.3

Methods............................................................................................................................. 92

3.3.1

Materials .................................................................................................................... 92

3.3.2

Cell Culture................................................................................................................ 92

viii
3.3.3

Preparation of AGE-BSA and BSA Concentration ................................................... 93

3.3.4

GSH Assay................................................................................................................. 93

3.3.5

ROS Assay................................................................................................................. 94

3.3.6

Glutathione Reductase Activity ................................................................................. 94

3.3.7

Cell Viability Assay................................................................................................... 94

3.3.8

Western Blotting........................................................................................................ 95

3.3.9

Neurite Quantification ............................................................................................... 95

3.3.10

Statistical Methods .................................................................................................. 96

3.4

Results ............................................................................................................................... 96

3.4.1

Impact of D3T and NAC on GSH status ................................................................... 96

3.4.2

Impact of D3T on Cell Viability and ROS Generation ............................................. 97

3.4.3

The Effect of D3T on G6PD...................................................................................... 98

3.4.4

The effect of D3T on Glutathione Reductase ............................................................ 98

3.4.5

The Effect of DHEA on Cell Viability and ROS Generation.................................... 99

3.4.6

The Effect of DHEA on Neurite Morphology ......................................................... 100

3.5

Discussion ....................................................................................................................... 100

3.6

References....................................................................................................................... 119
EFFECT OF DISRUPTING THE THIOL REDOX STATE ON NEURITE

DEGENERATION ..................................................................................................................... 126
4.1

Abstract ........................................................................................................................... 126

4.2

Introduction..................................................................................................................... 127

4.3

Methods........................................................................................................................... 129

4.3.1

Materials .................................................................................................................. 129

4.3.2

Cell Culture.............................................................................................................. 129

4.3.3

Lentiviral Transduction ........................................................................................... 130

4.3.4

Preparation of AGE-BSA and BSA Control ........................................................... 130

4.3.5

Western Blotting...................................................................................................... 131

4.3.6

Neurite Quantification ............................................................................................. 132

4.3.7

Statistical Methods................................................................................................... 132

4.4

Results ............................................................................................................................. 133

4.4.1

The Effect of GSSGme Treatment on Cell Morphology......................................... 133

ix
4.4.2

The Effect of AAPA Treatment on Cell Morphology ............................................. 133

4.4.3

The Effect of GSSGme and AAPA Combination on Cell Morphology.................. 134

4.4.4

The effect of AGE Treatment and Antioxidant Protection on Glutathionylation ... 134

4.4.5

Generation of Stable GRX-1 Knockdown SH-SY5Y Cells .................................... 134

4.5

Discussion ....................................................................................................................... 135

4.6

References....................................................................................................................... 150
SUMMARY AND FUTURE DIRECTIONS ................................................... 155

5.1

Summary ......................................................................................................................... 155

5.2

Future Directions ............................................................................................................ 158

5.3

References....................................................................................................................... 162

APPENDIX................................................................................................................................. 166

x

LIST OF FIGURES

Figure 1.1 Structure of the peripheral nerve. ................................................................................ 10
Figure 1.2 Polyol pathway. ........................................................................................................... 11
Figure 1.3 Polyol and PKC pathway interaction. ......................................................................... 14
Figure 1.4 The electron transport chain. ....................................................................................... 18
Figure 1.5 Formation of Amadori products. ................................................................................. 20
Figure 1.6 AGE-RAGE-mediated activation of NADPH oxidase................................................ 23
Figure 1.7 Structure of lipoic acid. ............................................................................................... 25
Figure 1.8 Structure of resveratrol. ............................................................................................... 26
Figure 1.9 Structure of 3H-1,2-dithiole-3-thione.......................................................................... 27
Figure 1.10 Regulation of Nrf2 activation and Nrf2-mediated gene transcription. ...................... 28
Figure 1.11 Structure of N-acetylcysteine. ................................................................................... 30
Figure 1.12 Glutathione synthesis pathway. ................................................................................. 32
Figure 2.1 Effect of NAC pre-treatment on GSH concentrations of BSA- and AGE-treated SHSY5Y cells. ................................................................................................................................... 66
Figure 2.2 NAC (1 mM) pre-treatment protects against AGE-induced GSH depletion............... 67
Figure 2.3 NAC pre-treatment confers complete protection against AGE-induced neurite
retraction. ...................................................................................................................................... 68
Figure 2.4 NAC pre-treatment confers complete protection against AGE-induced long neurite
loss. ............................................................................................................................................... 69
Figure 2.5 BSO (1000 μM) treatment results in depletion of cellular GSH. ................................ 70
Figure 2.6 BSO treatment induces neurite loss and 2 mM NAC pre-treatment confers protection.
....................................................................................................................................................... 71
Figure 2.7 BSO treatment has no significant impact on number of long neurites........................ 72
Figure 2.8 BSO treatment induces neurite loss and 2 mM NAC confers protection.................... 73

xi
Figure 2.9 BSO treatment decreases viability and NAC pre-treatment confers partial protection.
....................................................................................................................................................... 74
Figure 2.10 NAC does not restore GSH with BSO treatment. ..................................................... 75
Figure 2.11 NAC does not confer protection against AGE-induced neurite retraction following
BSO treatment............................................................................................................................... 76
Figure 2.12 NAC does not confer protection against AGE-induced neurite retraction following
BSO treatment............................................................................................................................... 77
Figure 2.13 NAC does not confer protection against AGE-induced long neurite loss following
BSO treatment............................................................................................................................... 78
Figure 2.14 NAC pre-treatment does not restore GSH after AGE-BSO treatment. ..................... 79
Figure 2.15 NAC does not confer protection against AGE-BSO-induced viability loss.............. 80
Figure 2.16 Synergistic role of GSH in the endogenous antioxidant defense system. ................. 81
Figure 3.1 NAC and D3T treatment increases total GSH........................................................... 105
Figure 3.2 D3T does not protect reduced GSH under AGE-treated conditions. ........................ 106
Figure 3.3 D3T exacerbates AGE-induced GSSG increase........................................................ 107
Figure 3.4 D3T exacerbates AGE-induced viability loss. .......................................................... 108
Figure 3.5 D3T exacerbates AGE-induced ROS generation. ..................................................... 109
Figure 3.6 D3T treatment results in increased G6PD protein expression................................... 110
Figure 3.7 Impact of NAC and D3T treatment on GR protein expression. ................................ 111
Figure 3.8 D3T treatment reduces GR activity in AGE-challenged cells................................... 112
Figure 3.9 DHEA inhibits AGE and D3T-induced ROS generation. ......................................... 113
Figure 3.10 G6PD inhibition protects against AGE and D3T-induced viability loss................. 114
Figure 3.11 DHEA protects against AGE-induced neurite retraction. ....................................... 115
Figure 3.12 DHEA protects against AGE-induced loss of long neurites. .................................. 116
Figure 3.13 DHEA protects against AGE-induced loss of long neurites and retraction. ........... 117
Figure 3.14 Mechanism of the D3T paradox. ............................................................................. 118
Figure 4.1 GSSGme treatment induces significant neurite retraction. ....................................... 139

xii
Figure 4.2 GSSGme induces neurite retraction. ......................................................................... 140
Figure 4.3 GSSGme treatment does not significantly induce loss of long neurites. .................. 141
Figure 4.4 AAPA treatment results in significant neurite thinning. ........................................... 142
Figure 4.5 AAPA treatment results in significant neurite degeneration. .................................... 143
Figure 4.6 AAPA treatment results in significant loss of long neurites. .................................... 144
Figure 4.7 AAPA treatment results in neurite thinning. ............................................................. 145
Figure 4.8 GSSGme and AAPA combination treatment results in neurite retraction. ............... 146
Figure 4.9 GSSGme and AAPA combination treatment results in dramatic loss of long neurites.
..................................................................................................................................................... 147
Figure 4.10 NAC treatment confers protection against AGE-induced glutathionylation........... 148
Figure 4.11 Lentiviral transduction does not knockdown GRX-1.............................................. 149

xiii

LIST OF ABBREVIATIONS

8-hydroxy-2'-deoxyguanosine

8-OH-dG

2-acetylamino-3-[4-(2-acetylamino-2carboxyethylsulfanylthiocarbonylamino)phenylthiocarbamoylsulfanyl]
propionic acid

AAPA

antibody for advanced glycation end products

Ab-RAGE

advanced glycation end products

AGE

protein kinase B

Akt

AMP activated protein kinase

AMPK

analysis of variance

ANOVA

aldose reductase

AR

antioxidant response element

ARE

Bovine retinal endothelial cells

BRECs

bovine serum albumin

BSA

L-buthionine-sulfoximine

BSO

chlorophenylhydrazone

CCCP

Centers for Disease Control and Prevention

CDC

3H-1-2-dithiole-3-thione

D3T

diacylglycerol

DAG

2′,7′-dichlorofluorescin diacetate

DCFHDA

dehydroepiandrosterone

DHEA

xiv

Dulbecco's Modified Eagle Medium

DMEM

dorsal root ganglion

DRG

dithiol dithiothreitol

DTT

endothelial nitric oxide synthase

eNOS

endothelin-1

ET-1

fetal bovine serum

FBS

glucose-6-phosphate dehydrogenase

G6PD

glyceraldehyde-3-phosphate dehydrogenase

GAPDH

γ-glutamylcysteine ligase

GCL

glutathione peroxidase

Gpx

glutathione reductase

GR

glutaredoxin-1

GRX-1

glutathione

GSH

oxidized glutathione

GSSG

oxidized glutathione methyl ester

GSSGme

glutathione S-transferase

GST

4-hydroxynonenal

HNE

heme oxygenase

HO-1

Kelch-like ECH associated protein 1

Keap 1

keap 1-hepatocyte knockout mice

Keap 1HKO

low-density lipoprotein

LDL

xv

alpha-lipoic acid

LPA

Ruboxistaurin

LY333531

malondialdehyde

MDA

mitochondrial respiratory chain

MRC

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

MTT

N-acetylcysteine

NAC

N-acetyl-p-benzoquinone imine

NAPQI

nerve blood flow

NBF

nerve conduction velocity

NCV

nitric oxide

NO

NAD(P)H:quinone oxidoreductase

NQO1

nuclear factor erythroid 2-related factor 2

Nrf2

oxidative stress

OS

poly(ADP-ribose) polymerase

PARP

phosphatidylinositol-3 kinase

PI3K

protein kinase C

PKC

peripheral neuropathy

PN

peripheral nervous system

PNS

ubiquinol

Q

ubiquinone

QH2

xvi
receptor for advanced glycation end products

RAGE

randomized control trial

RCT

reactive oxygen species

ROS

sorbitol dehydrogenase

SDH

deacetyl silent information regulator 2/sirtulin 1

SIRT1

superoxide dismutase

SOD

soluble advanced glycation end products

SRAGE

tricarboxylic acid

TCA

uncoupling protein-1

UCP-1

vascular endothelial growth factor

VEGF

xvii

ABSTRACT

Author: Stochelski, Mateusz, A. PhD
Institution: Purdue University
Degree Received: August 2018
Title: Regulation of the Endogenous Antioxidant Defense System in Diabetic Peripheral
Neuropathy.
Major Professor: John R. Burgess
Oxidative stress is implicated as a major contributor to the development of diabetes induced
peripheral neuropathy. This debilitating condition significantly impacts the quality of life of
patients, yet available treatment options are not optimal. They include tricyclic antidepressants,
anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake
inhibitors, and opiates. Unfortunately, these treatment options only reduce pain by 30-50%, and
many patients discontinue use due to side effects. Furthermore, the current treatment options are
focused on pain reduction, but not the protection of the peripheral nerves. Since oxidative stress
driven by high glucose concentrations has been implicated as the key factor causing peripheral
neuropathy, these studies focused on reducing or increasing protection against oxidative stress
using dietary compounds with antioxidant properties to ameliorate diabetic peripheral neuropathy.
Two dietary compounds with very different mechanisms of antioxidant protection were explored
in detail, N-acetylcysteine (NAC) and 3H-1,2-dithiole-3-thione (D3T). To model diabetic
peripheral neuropathy, differentiated SH-SY5Y cells were used and stressed with advanced
glycation end products (AGE), which form as a result of high glucose concentrations in vivo and
cause oxidative stress. In our initial studies, we showed that NAC conferred complete protection
against AGE-induced neurite degeneration via a glutathione-mediated mechanism. These studies
showed that maintenance of glutathione is critical for neurite structure, as inhibition of glutathione
synthesis under non-stressed conditions resulted in significant neurite degeneration. Our next focus

xviii
was on D3T, a potent nuclear factor (erythroid-derived 2)-like 2 (Nrf2) inducer. D3T generates its
antioxidant effect though upregulation of endogenous cellular antioxidant defenses. Previous
studies from our lab have shown that D3T treatment paradoxically exacerbates AGE-induced
damage, and these prior results were confirmed in the present studies. The mechanism by which
D3T potentiates damage was extensively studied. The results of the experiments indicated that
D3T potentiates AGE-induced oxidative stress via two critical pathways in the cell-based system
used. First, D3T upregulated the Nrf2 responsive gene glucose-6-phosphate dehydrogenase
(G6PD), leading to increased G6PD protein expression. Increased expression of G6PD resulted in
generation of reducing equivalents that are used by NADPH oxidases to generate superoxide. The
oxidative stress damage caused by superoxide generation was then amplified by D3T-mediated
reduction of glutathione reductase activity, which resulted in low cellular reduced glutathione
concentrations and high oxidized glutathione concentrations. In this manner, D3T inhibited the
effectiveness of the endogenous antioxidant defense system and led to disruption of the thiol redox
state. In the final set of studies, we found that AGE-induced oxidative stress resulted in a
significant increase of protein glutathionylation. Because D3T further disrupts the thiol redox state,
it conferred no protection against AGE-induced protein glutathionylation. However, NAC, which
was completely protective against AGE-induced neurite degeneration, was also able to fully
protect against protein glutathionylation under challenged conditions. Based on the combined
results, we conclude that maintenance of the thiol redox state is critical for maintaining neurite
morphology, and antioxidants such as NAC that protect the thiol redox state will confer neurite
protection in pro-oxidative conditions.

1

LITERATURE REVIEW

1.1

Introduction
The incidence of diabetes mellitus has been on the rise, increasing by approximately 1

million new cases every year [1]. Diabetes mellitus is a disease of poor glycemic control and as a
result many patients develop serious and sometimes debilitating complications such as
cardiovascular complications, retinopathy, nephropathy, and the major focus of this dissertation,
peripheral neuropathy (PN) [2–4]. PN is one of the most common and debilitating complications
of diabetes affecting at least 50% of patients [5,6]. Unfortunately, the medications available for
these patients come with severe side effects causing many people to discontinue their use [7].
The most effective treatment for PN is a return to normoglycemia, however this is not attainable
for the majority of patients [8,9]. Oxidative stress as a result of hyperglycemia has been linked to
the pathogenesis of peripheral neuropathy [8]. In the hyperglycemic state there is an increased
generation of reactive oxygen species (ROS) [2,10,11]. Prolonged exposure can exhaust the
endogenous antioxidant defense mechanisms and lead to cellular dysfunction and/or death. The
molecular targets of oxidative stress, lipids, DNA, and proteins are briefly reviewed in this
literature review. The major pathways of ROS generation, polyol pathway, protein kinase C
pathway, mitochondrial pathway, and advanced glycation end product pathway, are also
reviewed in great detail in regard to their contributions to the development of diabetic PN.
Because there are so few treatment options and because oxidative stress has been implicated in
development and progression of PN, antioxidants have been investigated as potential therapeutic
treatments for this disease. Here we review four antioxidants that show particular promise, with a
focus on cruciferous vegetable constituent 3H-1,2-dithiole-3-thione, and the commonly used
supplement N-acetylcysteine.

2
1.2

Overview of the Prevalence of Diabetes and Complications
Diabetes mellitus, a disease hallmarked by hyperglycemia, is one of the most common

chronic diseases worldwide and new diagnoses are on an upward trajectory [1]. Data from the
Centers for Disease Control and Prevention (CDC) is startling. In the span of just two years the
incidence of diabetes in the US population increased by one percent, amounting to 2.2 million
new cases. World prevalence in 2010 was estimated to be 6.4% and is projected to increase to
7.7% in 2030 [1]. Type 2 diabetes accounts for nearly 95% of all diagnosed cases, and lifestyle
choices such as inactivity have been linked to the risk of development of this disease [12]. With
more people beginning to lead a sedentary lifestyle and with approximately 37% of U.S. adults
having prediabetes, the upward trajectory of new cases is likely to continue increasing. This
poses a major problem for the healthcare field, as the direct medical costs for treating diabetics in
2012 was a staggering $ 176 billion [13]. With diabetes on the rise, it is important to investigate
the possible consequences of poor glycemic control.

1.3
1.3.1

Complications Due to Poor Glycemic Control
Cardiovascular Complications
Cardiovascular complications are the leading cause of diabetes related deaths, and

hyperglycemia induced oxidative stress plays a key role in promoting a proatherogenic
environment. In diabetic patients, atherosclerosis occurs earlier and is more aggressive
compared to nondiabetics [2]. The major sources of ROS generation in the hyperglycemic state
include: polyol pathway upregulation, protein kinase c (PKC) activation, the mitochondria, and
the formation of advanced glycation end products (AGEs) [14,15]. Studies have shown that the
hyperglycemic state can lead to increased endothelial NADPH oxidase activity and a resultant
increase in superoxide production [2,10,11]. Increased superoxide concentrations can lead to
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depletion of nitric oxide (NO) via oxidation to peroxynitrite, which can induce cardiac
remodeling by activation of matrix metalloproteinases and promote necrotic and apoptotic cell
death [2,16]. A decrease in NO also leads to inhibition of vasodilation and blood flow
abnormalities. This effect is magnified by the upregulation of endothelin-1, a potent
vasoconstrictor, which is induced by upregulation of PKC in the diabetic state [15,16].
Peroxynitrite and other ROS may also oxidize insulin receptors on peripheral tissue, further
contributing to the insulin resistance observed in diabetes [16]. Furthermore, buildup of
peroxynitrite can lead to oxidation of tetrahydrobiopterin, which promotes endothelial nitric
oxide synthase (eNOS) uncoupling [2]. Uncoupled eNOS can then transfer electrons to and
oxidize molecular oxygen, further increasing superoxide concentrations [2]. High levels of ROS
in the vasculature have been suggested to be responsible for increased oxidation of low-density
lipoprotein (LDL) [2]. The hyperglycemic condition has been shown to promote lipoprotein
lipase synthesis in macrophages, which further promotes lipoprotein accumulation in the
vasculature [17]. Macrophages then take up and store oxidized LDL and become foam cells,
which leads to an inflammatory state and progression of plaque buildup that is characteristic of
atherosclerosis [2,17,18]. Increased oxidative stress can also result in microvascular
complications which can contribute to the development of retinopathy, nephropathy, and
neuropathy.
1.3.2

Diabetic Retinopathy
Diabetic retinopathy is the leading cause of blindness in adults and is caused by damaged

microvasculature in the retina [3]. Prevalence of retinopathy in diabetics increases with the
duration of the disease and reaches 90% after 25 years [19]. A prolonged hyperglycemic assault
on the retinal microvasculature causes endothelial cell damage and leaky tight junctions that lead
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to retinal swelling [19]. Damaged endothelial cells cause further damage to the retina by
blocking blood flow in capillaries leading to ischemia [3]. To overcome decreased blood flow,
new capillaries begin to form [3]. However, without support, this ultimately leads to the
detachment of the retina [3]. The retina is especially susceptible to oxidative injury because it has
the highest glucose oxidation and oxygen consumption relative to other tissue [20]. Cell culture
models have shown an increase in mitochondrial superoxide accumulation in retinal cells [21]
and DNA and lipid peroxidation are observed in the retina under hyperglycemic conditions [3].
Sources of ROS generation in the retina are the same major sources linked to the general
hyperglycemic state. Endogenous antioxidant defenses can be compromised in the diabetic state.
For example, defects in gamma-glutamyl transpeptidase [22] result in a decrease of the
antioxidant glutathione (GSH) [23] in the retina under hyperglycemic conditions leaving it more
susceptible to oxidative injury.
1.3.3

Diabetic Nephropathy
Another leading microvascular complication commonly seen in diabetics, nephropathy,

has a 25% incidence in patients with type 2 diabetes for 10 years [4]. Diabetic nephropathy is
also the leading cause of end stage renal disease and is associated with increased cardiovascular
mortality [4,24]. In the hyperglycemic state, glomerular mesangial cells have been shown to
poorly regulate their intracellular glucose concentrations [25]. These cells are vital for
glomerular capillary structure and for glomerular filtration via smooth muscle activity. In
diabetic nephropathy these cells are damaged, and oxidative stress is a major factor [24]. The
major pathways of ROS generation are upregulated in the glomerular microvasculature [24].
Markers for oxidative stress are increased in diabetic patients with glomerular hyperfiltration, the
first phase of diabetic nephropathy [26]. Glomerular basement membrane thickening, a later
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phase of diabetic nephropathy, has been linked to accumulation of AGEs and the corresponding
decrease in NO availability [24,27]. Oxidative stress has been clearly implicated in the
pathogenesis of diabetic nephropathy [24], and treatment with antioxidants in animal models has
shown protection against ROS generation in the glomeruli [28].
1.3.4

Diabetic Neuropathy
PN affects at least 50% of diabetic patients, making it one of the most common

complications of diabetes [5,6]. Furthermore, patients with prediabetes or metabolic syndrome
are at elevated risk for development of PN [5]. Common symptoms of PN include decreased
sensitivity in the extremities and burning and shooting pain [29]. Approximately one third of
patients with PN experience pain, which begins in the lower limbs and can later spread to upper
limbs[29]. It is important to note that symptoms are not a good indicator of the severity of PN
and nerve conduction tests should be performed [29,30]. Approximately 15% of diabetics
experience foot ulcers and foot ulcers precede lower leg amputations 84% of the time [31].
Patients that do not develop painful PN and experience numbness in the extremities can be
particularly susceptible to developing ulcers. Oxidative stress as a direct result of hyperglycemia
has been linked to the pathogenesis of PN and the mechanisms will be described in detail in
subsequent sections. A thorough understanding of this debilitating condition is essential for
developing treatments for patients and improving their quality of life. The most effective
treatment for PN is a return to normoglycemia, however this is not an easy nor relatively feasible
task for many patients [8,9]. Current treatments for PN include tricyclic antidepressants,
anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake
inhibitors, and opiates [7]. Unfortunately, these treatments only reduce pain by at most 30-50%,
have a bevy of adverse side effects, and in some cases up to 20% of patients simply discontinue
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therapy due to negative side effects [7,32]. Therefore, reducing or increasing protection against
oxidative stress should be a key focus for ameliorating diabetic complications, and both animal
and human studies have shown protective effects with antioxidant therapy.

1.4
1.4.1

Overview of Oxidative Stress and its Molecular Targets
Oxidative Stress

Oxidative stress has been defined as the generation of toxic ROS that disrupts the balance
between antioxidants and oxidants in favor of oxidants [33]. Multiple pathways are responsible
for the increased generation of ROS in the hyperglycemic state that eventually leads to oxidative
stress. ROS such as superoxide, hydroxyl radical, and singlet oxygen are highly reactive due to
unpaired electrons in their outer electron shell [34]. These ROS can then react with molecular
targets such as proteins, lipids, and DNA [34]. Prolonged exposure can exhaust the endogenous
antioxidant defenses, leaving cellular macromolecules susceptible to oxidation and lead to
dysfunction and/or cell death.
1.4.2

Lipid Peroxidation
Damage to lipids caused by an imbalance of ROS can lead to cell dysfunction by

impairing the selective permeability of the phospholipid bilayer. Lipid peroxidation leads to the
formation of peroxyl fatty acid radicals which themselves are unstable and react with other fatty
acids in the phospholipid bilayer which promotes a chain of autocatalytic lipid peroxidation [35].
Vitamin E, the major lipophilic antioxidant, is known as a chain breaking antioxidant that can
stop this autocatalytic reaction and protect the integrity of the lipid bilayer. Glutathione also
plays a major role in protecting the lipid bilayer, as it is a substrate for the enzyme phospholipid
hydroperoxide glutathione peroxidase that reduces oxidized lipids [35]. Therefore, depletion of
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endogenous antioxidants under oxidative stress conditions can leave the cell susceptible to lipid
peroxidation.
1.4.3

DNA Oxidation
Another target for oxidation in a high ROS environment is DNA. The hydroxyl radical

and singlet oxygen can react with DNA nucleobases and lead to the formation of 8-hydroxy-2’deoxyguanosine (8-OH-dG) [36]. Other nucleobases can react with ROS, but 8-OH-dG is the
most common and has also been shown to be promutagenic [36]. For these reasons 8-OH-dG is
commonly used as a marker for DNA oxidation. Though there is conflicting data in the literature,
it has been shown that when base excision repair mechanisms are defective, ROS can directly
induce lethality in cell culture models [35]. In studies from our lab, the antioxidants alphatocopherol and N-acetylcysteine conferred protection against DNA oxidation in a cell culture
model of peripheral neuropathy using SH-SY5Y cells [37].
1.4.4

Protein Oxidation
Proteins are also susceptible to ROS mediated oxidation. The amino acids most subject to

oxidation contain either a sulfhydryl group or an aromatic side chain [34]. Methionine, a thiol
ether, can be readily oxidized to methionine sulfoxide under oxidative stress [38]. Most
organisms express methionine sulfoxide reductase, as methionine oxidation can impact protein
function [35,38]. Oxidative stress can also lead to disulfide bond formation, and both thioredoxin
and glutaredoxin systems in eukaryotic cells work to reduce protein disulfides [39]. Other amino
acids can form carbonyls when oxidized, but unlike thiol oxidation, this is not reversible.
Carbonylated proteins can form into toxic aggregates and accumulate overtime [35]. To counter
this, carbonylated proteins are ubiquitinated and then degraded by the proteasome [35].
However, the proteasome itself can be inactivated via oxidation, allowing for the buildup of toxic
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aggregates in a pro-oxidative environment [35]. The oxidation and inactivation of other
antioxidant enzymes such as superoxide dismutase can further disrupt the cellular endogenous
antioxidant defense mechanisms and promote a pro-oxidative condition [35].

1.5

Peripheral Neurons and Hyperglycemia
Peripheral nerves are highly susceptible to damage in the hyperglycemic state due to their

high expression of the glucose transporter GLUT1[40]. Both neuronal cells and Schwann cells
are unable to decrease glucose transport in response to increased blood glucose concentrations
[25]. GLUT1 has a very high affinity for glucose and operates at V max under normal blood
glucose concentrations (4.4 – 6.1 mM) and hyperglycemic conditions [41]. In mesangial cells,
saturation of this transporter has been reported at glucose concentrations of 30-35 mM [41].
Peripheral nerves have also been shown to have low GSH, glutathione peroxidase, and
glutathione reductase levels, making them especially susceptible to oxidative stress [42].
Therefore, peripheral nerves, due to their high expression of GLUT1 and low GSH status, would
be especially susceptible to hyperglycemia induced damage.
To better understand glucose uptake in the peripheral nervous system (PNS), a solid
understanding of glucose uptake physiology is required. According to an extensive review of
glucose transport in peripheral nerves by Magnani and colleagues, peripheral nerves have a very
high demand for glucose, as it is their major source of energy. In the neuron, the highest energy
demands are in nodes of Ranvier, where large amounts of ATP are required for the Na +/K+
ATPase. For glucose to enter the neuron, it must first pass both the perineurial diffusion barrier
and the blood-nerve barrier in the endoneurium. GLUT1 is highly expressed in these areas. After
passing through the endoneurium, glucose still needs to traverse through the Schwann cell and
the axolemma itself. Due to the anatomical structures of the Schwann cell and axolemma at the
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paranodal region, which makes up the paranodal diffusion barrier, it is believed to be the major
site of axonal glucose transport. Glucose is transported across the Schwann cell via GLUT1,
however it is not conclusive as to which glucose transporter is responsible for glucose transport
across the axolemma. In other lesser energy requiring sections of the axon such as the internode,
glucose enters the axon at the Schmidt-Lanterman incisure via GLUT1 mediated transport [40].
In summary, GLUT1 is the major glucose transporter in the peripheral nerve and is highly
expressed in the perineurium, endoneurium, and Schwann cells. It is also responsible for axonal
glucose uptake at the Schmidt-Lanterman incisures, but a novel glucose uptake pathway may
exist at the paranodal region of the axon.
Many studies and reviews that discuss oxidative stress in peripheral neuropathy
generalize the condition to the entire peripheral nerve. It is important to note that the peripheral
nerve consists of the epineurium, perineurium, endoneurium, Schwann cells, and the neuron
(Fig. 1.1). Hyperglycemia induced injury in the PNS can occur in any of these locations in vivo,
and where the cascade that initiates the development of diabetic PN originates is still a subject of
much debate [14]. In a review of the pathogenesis of diabetic PN, Cameron and colleagues stated
that even though hyperglycemia has been shown to directly affect the neuron, these effects could
be caused by compromised blood delivery [43]. The endoneurium has been shown to be hypoperfused and hypoxic in the diabetic state, a condition that is secondary to a reduction in nerve
blood flow (NBF) and increased endoneurial vascular resistance [44]. Vasodilators such as NO
are decreased in the diabetic state, and a strong positive correlation has been shown between
correction of endoneurial perfusion deficits and nerve conduction improvements [43]. The
pathogenesis of diabetic PN is multi-factorial, and the following sections will cover the major
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pathways of hyperglycemia induced oxidative stress and their role in the development of this
debilitating diabetic complication.

Figure 1.1 Structure of the peripheral nerve.
Reprinted with permission from Taylor & Francis [45].

1.6
1.6.1

Four Major Sources of ROS Generation in Diabetic Peripheral Neuropathy
Polyol Pathway
The role of the polyol pathway in diabetic PN has been extensively studied and reviewed.

This pathway consists of two enzymes, aldose reductase (AR) and sorbitol dehydrogenase (SDH)
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(Fig. 1.2). AR has a low affinity for glucose, but in the hyperglycemic state glucose flux through
this pathway increases [15]. Via an NADPH dependent process, AR then reduces glucose to
sorbitol [15]. A large number of studies have been conducted that have identified why increased
polyol pathway flux leads to development and progression of diabetic PN, and the Obrosova
review provides an excellent summary [46].

Figure 1.2 Polyol pathway.
Reprinted with permission from Springer Nature and Copyright Clearance Center, Inc. [15].

Increased glucose flux through the polyol pathway leads to increased generation of
fructose. Fructose is a ten times more powerful glycating agent compared to glucose which can
have the effect of increased formation of AGEs (discussed in detail in subsequent section),
activation of the receptor for advanced glycation end products (RAGE), and the downstream
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increased production of ROS [46]. Oxidation of sorbitol to fructose by SDH is mediated by
reduction of NAD+ to NADH. An increase in the NADH:NAD+ ratio can lead to decreased
activity of glyceraldehyde-3-phospahte dehydrogenase (GAPDH) [15]. GAPDH catalyzes the
formation of 1,3- Diphosphoglycerate from triose phosphate via an NAD + dependent mechanism
in glycolysis. Inhibition of this enzyme leads to build up of triose phosphate which itself can
increase formation of methylglyoxal, a precursor of AGE formation, and diacylglycerol (DAG),
a PKC activator [15,47]. SDH inhibitors or mutations however, have not been shown to be
protective against development of PN suggesting that AR is the responsible enzyme [43,48,49].
AR reduces glucose to sorbitol via an NADPH dependent mechanism, and as such
increased flux through the polyol pathway can deplete cellular NADPH stores [15]. Depletion of
NADPH stores would limit the activity of glutathione reductase and increase the ratio of
oxidized glutathione (GSSG) to GSH. Depletion of glutathione, the bodies’ major biological
antioxidant, has been linked to increased intracellular oxidative stress and diabetic complications
[43,50]. Animal studies have shown promising effects in both the use of AR inhibitors and AR
knockout.
Studies done on diabetic rats have shown that diabetes leads to a decrease in total nerve
GSH, an increase in buildup of nerve malondialdehyde (MDA), a decrease in nerve conduction
velocity (NCV), and a decrease in NBF [49]. Treatment with AR inhibitor restores GSH loss,
counters superoxide production in the vasa nervorum, corrects NBF deficits, and prevents
elevation of nerve MDA [46,49]. The AR inhibitor Fidarestat was also able to correct motor and
sensory never conduction velocity in a dose dependent fashion in a diabetic rat model [46,51].
Furthermore, Chung and colleagues developed an AR gene knockout mouse model. Under
diabetic conditions, wild-type mice had significantly depleted nerve GSH levels and decreased
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NCV. Under these same conditions, AR null mice were able to maintain normal GSH levels, and
there was no change in NCV [48]. These results clearly implicate AR as a major contributor of
oxidative stress and nerve function impairment that is seen in diabetic peripheral neuropathy.
Human studies however, have had mixed results.
It is reported that patients with diabetes on average experience an approximate 0.5m/s
drop in NCV [52]. In a 60-week study of the AR inhibitor Ranirestat, a 20mg/day dose decreased
sorbitol levels by 83.5% and had a significant effect on increasing NCV in peroneal motor, right
sural, and proximal median sensory nerves. Peroneal motor and right sural NCV improved by
~1m/s whereas the proximal median sensory nerve saw an improvement of 3.4 m/s [53].
However, this study was not placebo controlled, and a follow up placebo-controlled study was
performed by the same group. In the follow up study, 20 mg/day Ranirestat showed similar
improvement to peroneal motor NCV. Sensory nerve function was not improved compared to
placebo, but this was largely due to an overall increase in NCV in the placebo group [54]. The
authors attributed this to lifestyle modifications of the patients in the study. Another study using
a different AR inhibitor, Zenarestat, at dosages decreasing sorbitol levels by more than 80%
increased small-diameter sural nerve myelinated fiber density [53,55]. AR inhibitors have shown
promise for patients with diabetic PN, but further follow up studies should be conducted to better
ascertain the clinical efficacy of AR inhibitors.
1.6.2

PKC Pathway
PKC overactivation has also been linked with the development of diabetic PN, so a brief

overview of activation and the downstream targets is warranted [56]. There are at least 11
isoforms of PKC, with 9 activated by DAG [15]. Hyperglycemic conditions promote de novo
synthesis of DAG in vascular tissue due to increases in glycolytic pathway intermediates. De
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novo synthesis of DAG requires glycolytic intermediate triose phosphate and stepwise acylation
catalyzed by glycerol-3-phosphate acyltransferase and monoacylglycerol-3-phosphate
acyltransferase [57]. The hyperglycemic state has been shown to increase activity of the polyol
pathway, with as much as 30% of glucose shunted through this pathway [48]. Increased activity
of SDH can lead to a depletion of cellular NAD + and suppressed activity of GAPDH[15].
Suppressed activity of GAPDH in the glycolytic pathway will lead to build up of triose
phosphate, and as such can contribute to the increase in DAG seen in the hyperglycemic state.
The interaction between the polyol and PKC pathways is shown in Figure 1.3.

Figure 1.3 Polyol and PKC pathway interaction.
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Of all the isoforms of PKC, PKC-β has gathered the most attention with regards to the
development of diabetic PN. Overactivation of PKC-β has been associated with diabetic PN
mainly through dysregulation of the microvasculature [56]. Upregulation of PKC-β has been
linked with inhibition of eNOS and upregulation of endothelin 1 (ET-1), vascular endothelial
growth factor (VEGF), and NADPH oxidase [58]. Phosphorylation of eNOS leads to a decrease
in NO production, leading to blood flow abnormalities due to inhibited vasodilation [15,59]. This
effect is multiplied by increased expression of ET-1, a powerful vasoconstrictor [58]. Increased
VEGF expression can promote vascular permeability [15], and PKC activation in diabetes has
been linked with increased permeability of endothelial cells to macromolecules [58].
Upregulation of NADPH oxidase leads to an increase in generation of superoxide which can
promote formation of peroxynitrite, leading to uncoupling of eNOS and decreased NO
availability. PKC activation of NADPH oxidase is linked to the AGE-RAGE pathway that will
be discussed in a later section. Taken together, these effects lead to a decrease in nerve perfusion
and oxygenation which can lead to nerve damage and neuropathy.
The role for PKC-β in the development of diabetic PN, however, has been disputed. Early
studies showed that PKC activity was decreased in the diabetic peripheral nerve and
corresponding DAG was also shown to be decreased [60,61]. In a more recent study specifically
looking at the neovasculature of diabetic rats, the authors found that the PKC-β inhibitor
LY333531 (Ruboxistaurin) was able to correct nerve dysfunction. In diabetic animals,
endoneurial blood flow was reduced by approximately 50%, and motor and sensory NCV was
reduced by 19.7% and 13.9%, respectively. A high dose of LY333531 (10 mg kg-1 day-1) was
able to completely reverse both the endoneurial blood flow and decrease in NCV [59]. This data
supports other studies that have been done on PKC inhibitors that show improvement in NBF
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and NCV in diabetic rats [49]. Further evidence supporting that PKC-β promotes diabetic PN via
a neurovascular method comes from a study using a nitric oxide synthase inhibitor. This inhibitor
attenuated the protective effects of PKC inhibition on diabetic rat peripheral nerves [62]. PKC-β
has been shown to be tyrosine phosphorylated by H2O2 treatment in a cell culture model of
monkey kidney cells [63]. Other studies have implicated oxidative stress and oxidized LDL in
PKC stimulation [49,64]. These other methods of activation are of importance because some
studies have shown that DAG concentrations are decreased in diabetic peripheral nerves [65].
Though PKC-β inhibition has shown improvements in neurovascular blood flow and
sensory and motor nerve conduction, human studies have at best shown a trend towards
significance. A recent systematic review was conducted on randomized control trials (RCTs) for
Ruboxistaurin. Of the six reviewed RCTs, four studies reported significant improvements in the
neurological total symptoms score. Vibration detection threshold was only measured in one
study and showed minor improvements in a subgroup of patients with clinically significant
symptoms. Importantly, out of four studies that measured C-fiber mediated skin microvascular
blood flow, three studies showed a significant increase from baseline after Ruboxistaurin
treatment. The authors concluded that even though treatment did show some benefits, there was
not enough data available to make any conclusions [66]. In future studies, it may be of interest to
co-treat patients with both Ruboxistaurin and antioxidants such as vitamin E and alpha-lipoic
acid (LPA). Co-treatment with a low dose of Ruboxistaurin and vitamin E or LPA in diabetic
rats completely corrected both endoneurial blood flow and NCV. Without co-treatment with
antioxidants, only ~20% improvement was observed [59]. The possible mechanism of action for
antioxidants could be that they protect against the buildup of superoxide and eNOS uncoupling,
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thus preventing peroxynitrite formation and NO depletion. Furthermore, vitamin E should be of
vital interest due to its ability to lower DAG levels by stimulating DAG kinase [49,59].
1.6.3

Mitochondrial Pathway
Hyperglycemia also induces mitochondrial ROS generation. To better understand

mitochondrial ROS generation, a brief overview of the electron transport chain is warranted. In
glycolysis, glucose oxidation yields the formation of pyruvate and generation of NADH.
Pyruvate can then be transported to the mitochondria and enter the tricarboxylic acid cycle
(TCA). Pyruvate oxidation then yields NADH (4) and FADH 2 (1) electron donors. At complex
one, NADH transfers two electrons to ubiquinol (Q) and reduces it to ubiquinone (QH2). QH2
then leaves complex one and enters the interior of the membrane. This cycle leads to pumping of
four protons out of the mitochondria and into the cytosol. Complex two also generates QH2, but
the electrons are initially donated from FADH2. Electrons from QH2 are then transferred to
complex three. At complex three (ubiquinol:cytochrome c oxidoreductase) electrons are
transferred to cytochrome c by the ubisemiquinone radical generating Q cycle [67]. Four protons
are transferred to the cytosol, two from QH2, and two directly from the matrix. At complex four
(cytochrome c oxidase), cytochrome c is oxidized and electron transfer proceeds to molecular
oxygen resulting in the release of water. This electron transport process creates a proton
concentration that is much lower in the matrix, generating an electric field with the matrix side
being negative. The proton gradient is crucial for ATP generation at complex five (ATP
synthase). Figure 1.4 illustrates the electron transport chain.
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Figure 1.4 The electron transport chain.
Reprinted with permission from Springer Nature and Copyright Clearance Center, Inc. [15].

Hyperglycemia induces perturbations in glycolysis that lead to increased transport of
pyruvate into the mitochondria and an increase of TCA derived electron transporters (NADH and
FADH2). An increase of these electron transporters increases the efflux of protons into the
cytosol (10 protons per electron pair from NADH, 6 for FADH2) and generates a high
electrochemical gradient. When the electrochemical gradient is high it increases the life of
superoxide generating electron transport intermediates such as ubisemiquinone [67].
Overexpression of Mn superoxide dismutase (SOD), uncoupling protein-1 (UCP-1), and
treatment with chlorophenylhydrazone (CCCP) (an uncoupler of oxidative phosphorylation that
abolishes the proton gradient) all prevent hyperglycemia induced intracellular ROS production in
bovine aortic endothelial cells [67].
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It has been proposed that mitochondrial superoxide production in the hyperglycemic state
is the initiating event for activating mechanisms such as polyol pathway, PKC activation, and
AGE formation that lead to progression of diabetic complications [15]. Brownlee and colleagues
were able to show that disrupting oxidative phosphorylation with CCCP, decreasing the
electrochemical gradient by upregulating UCP-1, and decreasing mitochondrial ROS by
upregulating MnSOD prevented activation of all three mechanisms [15,67]. They proposed that
the mechanism linking all these pathways of hyperglycemia induced damage is hyperglycemia
induced GAPDH inhibition. The authors claim that GAPDH activity under these conditions is
suppressed because increased mitochondrial ROS production induces DNA damage and activates
poly(ADP-ribose) polymerase (PARP). PARP can then make polymers of ADP-ribose which
accumulate on GAPDH and prevent its activity [68]. Inhibition of GAPDH could lead to
increased glucose shunted through the polyol pathway, and the increase in triose phosphate can
lead to increased DAG production and PKC activation, and AGE formation from methylglyoxal
[15]. In cultured aortic endothelial cells, GAPDH inhibition elevated the three pathways of
hyperglycemic damage to the same extent as hyperglycemia [68,69]. Mitochondrial generation
of ROS may be a unifying mechanism for ROS generation under hyperglycemic conditions in
endothelial cells, but recent studies on DRG neurons isolated from diabetic rats suggest there
may be other mechanisms.
A thorough review of mitochondrial dysfunction in sensory neuropathy was recently
written by Fernyhough et al [70]. In brief, mitochondrial respiratory chain (MRC) activity was
analyzed in DRG neurons of diabetic rats. Interestingly, at 22 weeks of diabetes there was a
significant decrease in MRC activity. Gene expression studies confirmed this phenomenon by
showing that components of both complex I and complex IV were downregulated. In vitro
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studies using sensory neurons from diabetic rats showed that the mitochondria of diabetic axons
are more depolarized compared to control cells. A decrease in generation of the electrochemical
gradient will decrease energy production through complex V. Further studies confirmed that the
decrease in mitochondrial function correlated with decreased ROS production in diabetic
mitochondria axons compared to control. The authors concluded that though there is an increase
in ROS production in diabetic axons, the likely source is not the mitochondria. However, the
observed decrease in ATP production is an important factor to consider in PN, as it decreases
excitation, axonal transport, and growth cone motility [70].
1.6.4

AGE Pathway

Figure 1.5 Formation of Amadori products.
Reprinted with permission from the American Chemical Society [71].
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Another pathway commonly linked with the progression of diabetic PN is the formation
of AGEs and their interaction with receptors such as RAGE. For an extensive review of AGE
synthesis, the Nessar Ahmed review is a great source [72]. In the classical AGE pathway,
glucose or other reducing sugars such as fructose react with a free amino group on a protein
forming an unstable Schiff base. The Schiff base then degrades into a more stable Amadori
product (Fig. 1.5) which with further rearrangement, oxidation, and elimination leads to the
formation of AGEs [73]. Reactive dicarbonyls also contribute to AGE synthesis, especially in the
diabetic condition [73]. As was discussed previously, a decrease in GAPDH activity is observed
under hyperglycemic conditions. As a direct result of hyperglycemia, more glucose is shunted
through the polyol pathway, leading to an increase in fructose. Fructose is more reactive than
glucose, and elevated levels lead to AGE synthesis [72,73]. There is also a build-up of triose
phosphate which leads to increased conversion to methylglyoxal, a reactive dicarbonyl. Reactive
dicarbonyls are gaining traction as one of the main mechanisms driving AGE synthesis as they
are 20,000 times more reactive than glucose [73]. In the diabetic state there is a significant
increase in both dicarbonyl and AGE synthesis, as well as AGE accumulation in the peripheral
nerves (axoplasm, Schwann cells, endoneurial and epineurial microvessels, perineurial basal
lamina, and perineurium) [73,74].
In the peripheral nerve, RAGE is localized in the microvasculature and on the axons
themselves. Experiments done on mice have shown the importance of RAGE in the development
of diabetic complications. RAGE knockout mice were partially protected from diabetes induced
pain perception loss. Wild type animals treated with soluble RAGE (sRAGE) showed similar
results. RAGE knockout mice were also protected from increased activation of PKC-β and NFКβ pathways [46]. In rats the use of an inhibitor of AGE formation, pyridoxamine, reversed
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diabetes induced decrease in NBF and motor and sensory NCV [46]. The AGE-RAGE axis has
clearly been implicated with the progression of diabetic PN in animal models; therefore, a further
look into the mechanism of action of this axis is warranted.
To elucidate the mechanism of action of the AGE-RAGE axis, Vincent et al first isolated
dorsal root ganglia (DRG) from Sprague Dawley rats. RAGE was shown to be localized
throughout the entire neuron. DRG neurons were then treated with the RAGE ligand S100,
which lead to a significant increase in ROS production. Cells that were incubated with sRAGE or
an antibody to rage (Ab-RAGE), which prevents RAGE from binding to ligands, showed a 70%
and 80% decrease in ROS formation, respectively. NADPH oxidase was upregulated with the
activation of RAGE, accounting for the observed increase in ROS. NADPH oxidase upregulation
was inhibited with both sRAGE and Ab-RAGE treatment. The authors concluded that RAGE
activates NADPH oxidase via a phosphatidylinositol-3 kinase (PI3K)/ protein kinase B (Akt)
pathway. However, activation of Akt alone was not sufficient to increase NADPH oxidase
activity, suggesting further downstream mechanisms of activation [75].
Studies done on endothelial and mesangial cells have shed more light on establishing a
pathway of NADPH oxidase activation. In both an animal model of diabetic nephropathy and
cell culture model using primary rat mesangial cells, Thallas-Bonke et al observed that inhibition
of PKC-α had similar results to apocynin inhibited NADPH oxidase in preventing cytosolic ROS
generation. PKC-α likely phosphorylates p47phox which allows for the assembly and activation of
NADPH oxidase [76]. In endothelial cells it has been shown that PKC-ζ is responsible for
phosphorylating p47phox, and that the upstream activation of PI3K is critical in the activation of
NADPH oxidase [77]. This pathway may be the missing step that was observed in the Vincent et
al study in DRG neurons. Further studies done on bovine retinal endothelial cells (BRECs)
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confirmed that AGE treatment enhanced ROS generation. It was also observed that p47 phox was
activated and translocated to the membrane from the cytosol after AGE treatment (Fig. 1.6).
Inhibition of NADPH oxidase with apocynin prevented the increase in ROS generation. Use of
PKC-β inhibitor LY379196 also completely prevented ROS production and p47 phox translocation
[78]. These studies confirm that the AGE-RAGE axis plays a key role in ROS generation, and
that ROS is generated by NADPH oxidase activated by PKC. Future studies will need to be done
on peripheral nerves to confirm that these pathways are also specific to the nerve vasculature and
to neurons and axons themselves.

Figure 1.6 AGE-RAGE-mediated activation of NADPH oxidase.

The AGE-RAGE axis may be especially critical in the generation of ROS and subsequent
development of diabetic PN because of the link to NF-Кβ. Activation of RAGE leads to
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intracellular signaling and activation of NF-Кβ [79]. Translocation of NF-Кβ to the nucleus
induces expression of many genes including ET-1, one of the most potent vasoconstrictors, and
RAGE itself [80]. NF-Кβ is also redox sensitive [67,74,80] and activation can lead to increased
RAGE expression which can lead to increased activation of the AGE-RAGE axis and ROS
generation. This creates a positive feedback loop and prolonged NF-Кβ activation that
overwhelms the endogenous autoregulatory feedback inhibition loop [79]. Prolonged NF-Кβ
activation leading to increased ET-1 expression can also contribute to endothelial cell
dysfunction and be partly responsible for the observed decrease in endoneurial blood flow that is
seen in diabetic PN [80]. Since NF-Кβ is also a regulator of many apoptotic genes such as FasLigand, it is possible that prolonged activation may also directly lead to apoptosis [81].
Therefore, intracellular signaling initiated by activation of the AGE-RAGE axis plays a critical
role in the development of diabetic PN.
1.6.5

Summary of ROS Generating Pathways
All of the ROS generating pathways described in this literature review are interconnected

and can activate each other in a variety of different ways. As an example, the hyperglycemic
state leads to more glucose being shunted through the polyol pathway as well as more pyruvate
entering the mitochondria. In the mitochondria this can lead to a disruption of the
electrochemical gradient, and as a consequence increased ROS generation. Increased activity of
AR can deplete NADPH stores and limit the activity of glutathione reductase. Further oxidation
of sorbitol to fructose would increase the NADH:NAD+ ratio which could decrease the activity
of GAPDH. The resulting buildup of triose phosphate would lead to increased synthesis of
AGEs. Activation of the AGE-RAGE axis would lead to downstream activation of PKC, which
would then activate NADPH oxidase and promote further ROS generation. Increased ROS and
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reduced activity of glutathione reductase would increase the GSSG:GSH ratio, impairing the
endogenous antioxidant defense of neurons and making them more susceptible to macromolecule
oxidation. Returning to normoglycemia would reduce ROS generation through these
interconnected pathways, but because this is not readily achievable for many patients it is
important to look at alternative treatments.

1.7
1.7.1

Potential Therapeutic Antioxidants
Lipoic Acid

Figure 1.7 Structure of lipoic acid.

Lipoic acid (LPA) is a potent thiol antioxidant that plays a key role in the antioxidant
network. When vitamin E becomes oxidized, it can be reduced back by vitamin C. Oxidized
vitamin C can then be reduced back to its reduced form by GSH. In the mitochondria, LPA can
be further reduced to dihydrolipoate by lipoamide dehydrogenase. Dihydrolipoate is a powerful
reductant that is capable of direct scavenging of radicals, regenerating vitamins E and C,
increasing potency of the entire redox antioxidant network, and upregulating levels of GSH [82].
Endothelial cells treated with AGE showed a 64% reduction in GSH levels and dramatic
reduction in reduced ascorbic acid. The increased oxidative stress was shown to activate NF-Кβ.
Treatment with LPA restored intracellular GSH and reduced ascorbic acid levels as well as
prevented nuclear translocation of NF- Кβ [80]. In diabetic rats with PN, LPA treatment
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significantly improved sensory NCV, endoneurial nutritive NBF, GSH levels, and normalized
the GSH:GSSG ratio [83]. Most importantly, the protective results of LPA treatment have also
been observed in humans. LPA has been shown to improve neuropathic symptoms in patients
with diabetic PN in multiple studies [84–86].
1.7.2

Resveratrol

Figure 1.8 Structure of resveratrol.

Resveratrol is gaining traction as a neuroprotectant because it has been shown to be an
effective hydroxyl and superoxide radical scavenger [87]. Resveratrol has also shown protection
against ROS-induced lipid peroxidation and DNA damage [87]. Resveratrol, through deacetylase
silent information regulator 2/sirtuin 1 (SIRT1), also upregulates MnSOD and increases cellular
GSH levels in endothelial cells [88]. SIRT1 also protects against GAPDH translocation from the
cytosol to the nucleus [89]. GAPDH normally resides in the cytosol, but is translocated to the
nucleus after apoptotic stimulation [90]. Here it regulates acetylation and subsequent activation
of proteins such as p53 that are part of the apoptotic cascade [89]. In the axons of diabetic
neurons, mitochondrial activity is decreased, and the AMP/ATP ratio begins to rise. AMPactivated protein Kinase (AMPK) is a sensor for high AMP levels that becomes phosphorylated
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under these conditions. It can then enhance mitochondrial function to increase ATP production.
DRG sensory neurons of diabetic rats have depressed AMPK signaling. Treatment with
resveratrol was able to cause direct activation of AMPK and normalize thermal sensitivity [70].
In another study, resveratrol treatment of rats with diabetic PN significantly improved motor
NCV, NBF, and decreased thermal hyperalgesia [91]. Clinical trials in diabetic patients with PN
have not been done on resveratrol, but this would be the logical next step given the positive
results seen in animal models.
1.7.3

3H-1,2-dithiole-3-thione (D3T)-Upregulation of the endogenous antioxidant defense
system

Figure 1.9 Structure of 3H-1,2-dithiole-3-thione.

3H-1,2-dithiole-3-thione (D3T) is a dithiolethione found in cruciferous vegetables such
as Brussels sprouts. This compound has garnered interest as a potential neuroprotectant due to its
nuclear factor-erythroid 2-related factor 2 (Nrf2) inducing properties and corresponding
upregulation of antioxidant genes [92–95]. Nrf2 is a transcription factor regulated by Kelch-like
ECH-associated protein 1 (Keap1). Nrf2 when bound by Keap1 is targeted for proteasomal
degradation via the Cullin-3-based E3 ligase complex. However, in response to oxidants or
electrophiles, Nrf2 is released from Keap1 by phosphorylation of Nrf2 or modification of critical
cysteine thiols on either Keap1 or Nrf2 and then translocates to the nucleus. Nrf2 then binds to
the antioxidant response element (ARE) and forms a heterodimer to transcriptionally activate a

28
host of antioxidant genes (Fig. 1.10). Upregulation of phase II metabolism enzymes such as
NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione S-transferase (GST), γglutamylcysteine ligase (GCL), and heme oxygenase 1 (HO-1) has made Nrf2 a target for
research on chemoprotection and oxidative stress [96].

Figure 1.10 Regulation of Nrf2 activation and Nrf2-mediated gene transcription.
Permission to reprint obtained from Copyright Clearance Center, Inc. [97]

The mechanism for how D3T upregulates Nrf2 expression is not entirely elucidated and
more than one mechanism may be responsible. In zebra fish embryos, D3T was shown to
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conjugate to regulatory cysteine 151 on Keap1 and lower Nrf2 degradation [95]. Keap1 has 25
reactive cysteines that can be modified by oxidation, reduction, or alkylation. Nrf2 has only
seven reactive cysteine residues; therefore, Keap1 has been referred to as being a “redox sensor.”
However, cysteine 199 on Nrf2 may be of particular importance as it has been shown to regulate
nuclear localization [98]. Interestingly, D3T may show protection by increasing superoxide
generation when reacting with thiols. Jia et al. measured superoxide generation during the
reaction of D3T with the dithiol dithiothreitol (DTT) and the thiol GSH. Reaction with either
molecule resulted in increased oxygen consumption and superoxide generation in a concentration
dependent manner. Superoxide production was more readily induced with DTT which may more
readily mimic the adjacent sulfhydryl groups located on Keap1 [94]. Therefore, D3T may
upregulate nuclear translocation of Nrf2 by directly interacting with reactive cysteine residues on
Keap1 as well as by generating ROS when reacting with sulfhydryl groups such as those found
on Keap1.
D3T treatment has been shown to be protective against neurotoxicity in SH-SY5Y cells,
primary human neurons, and human primary astrocytes [99,100]. In SH-SY5Y and primary
human neuronal cells, treatment with up to 100 μM D3T increased both total and mitochondrial
GSH and increased NQO1 activity. Dopaminergic neurons may be particularly susceptible to
oxidative stress as dopamine is readily oxidized to 6-hydroxydopamine. D3T pretreatment was
protective against 6-hydroxydopamine stress in SH-SY5Y and primary human neuronal cells
[99]. In vivo experiments with D3T have been carried out in mouse and rat models, but
protection against PN has not been directly studied [101–104]. In both mouse and rat models,
D3T treatment lead to upregulation of many Nrf2 responsive genes. However, the pattern of
response varied among different genes and tissues [101–103]. Therefore, further studies will
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need to be carried out in in vivo models of diabetic PN to determine whether D3T’s Nrf2
inducing properties confer protection in the peripheral nerve.
1.7.4

N-acetylcysteine (NAC)

Figure 1.11 Structure of N-acetylcysteine.

N-acetylcysteine (NAC) is an antioxidant that has been commonly used since the mid1970s as a first line of defense against acetaminophen poisoning [105,106]. Metabolism of
acetaminophen leads to the formation of reactive intermediate N-acetyl-p-benzoquinoneimine
(NAPQI), which is cleared after conjugation with GSH [107]. Once GSH is depleted, NAPQI
reacts with proteins and enzymes, which can lead to toxicity and cell death [105]. NAC protects
against acetaminophen toxicity by both increasing GSH production, and as a free radical
scavenger reducing NAPQI to acetaminophen [105,107]. Therefore, further review of these
potential mechanisms of action is warranted.
Cysteine is the rate limiting amino acid of GSH synthesis, and under physiological
conditions GCL is not operating at its maximal rate [106]. Therefore, increasing the cysteine
pool results in increased GSH synthesis and replenishment [106,108,109]. Active transport is
required for cysteine transport into the cell via the alanine-serine-cysteine system [106].

31
However, NAC is membrane permeable and does not require active transport to be taken up
[106,109]. After entering the cell NAC is hydrolyzed to yield cysteine, increasing substrate for
GCL and allowing for increased GSH synthesis (Fig. 1.12) [109]. Due to these reasons, NAC is
commonly used as a supplement to increase GSH levels [106,109,110]. In human clinical trials,
NAC has been shown to confer protection by replenishing GSH in HIV-infected individuals
[111] and in acetaminophen toxicity [107]. NAC supplementation has also been shown to reduce
postprandial markers of oxidative stress in patients with type 2 diabetes or impaired glucose
tolerance, however the mechanism of NAC protection was not established [112]. In a cell
culture model of diabetic neuropathy using SH-SY5Y cells, NAC treatment protected against
AGE-induced GSH depletion and conferred full protection against neurite degeneration [37]. In
cultured cerebellar granule neurons, the addition of lipid peroxidation byproduct 4hyroxynonenal (HNE) induced neuronal death. HNE treatment resulted in depletion of GSH and
a significant decrease in mitochondrial membrane potential. NAC supplementation prior to HNE
treatment resulted in complete protection against neuronal death and decrease in mitochondrial
membrane potential, and partial but significant protection of GSH. The mechanism of NAC
protection was attributed to maintenance of intracellular GSH, as GSH-HNE conjugation is
required for HNE detoxification [113]. NAC supplementation in cell culture has also shown
protection against ROS through a potential glutathione dependent mechanism in spinal motor
neurons [114], oligodendrocytes [115], cortical neurons [116], and PC-12 cells [117]. In diabetic
rats, NAC supplementation protected both reduced protein thiols and GSH levels and conferred
protection against the diabetes induced lipid peroxidation byproduct, MDA. Furthermore, the
diabetic rats experienced significant impairment of motor coordination, and NAC
supplementation was able to significantly improve motor coordination to 77.84% of control. The
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authors attribute the protective effects of NAC observed in this study to both its free radical
scavenging and GSH maintaining properties [118].

Figure 1.12 Glutathione synthesis pathway.
Reprinted with permission from Elsevier and Copyright Clearance Center, Inc. [119].

1.8

Research Questions
As was summarized in this literature review, ROS and oxidative stress play a significant

role in the development of diabetic PN. Both in vitro and in vivo studies have shown the potential
beneficial effects of antioxidants on protection against diabetic PN. Further research on
establishing the mechanisms of protection of antioxidants in PN is critical, as this may provide
diabetic patients more information and tools to improve their quality of life. This dissertation
will focus on two particular antioxidants, NAC and D3T, in a validated cell culture model of
diabetic PN.
The second chapter of this dissertation focuses on the mechanism of protection of NAC.
Previously in our lab, we were able to show that when differentiated SH-SY5Y cells were
stressed with AGE they experienced neurite and viability loss along with depletion of
intracellular GSH. NAC pre-treatment was able to completely protect against AGE-induced
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damage, and also maintained intracellular GSH concentrations. However, what was not
established was whether NAC was also conferring protection via its intrinsic antioxidant
scavenging properties. The mechanism of NAC protection is critical to understand for both the
role of GSH in neurite protection as well as later translation into in vivo studies. It was
hypothesized that NAC confers protection against AGE-induced neurite degeneration entirely
through maintaining intracellular reduced GSH concentrations, and not through the chemical’s
intrinsic antioxidant properties.
The third chapter of this dissertation focuses on the D3T paradox that was previously
discovered. Initially, it was hypothesized that D3T would confer protection against AGE-induced
damage in much the same way as NAC. D3T is potent Nrf2 inducer that has been shown to
upregulate enzymes required for GSH synthesis. However, D3T was only able to protect against
hydrogen peroxide-induced stress, but paradoxically exacerbated AGE-induced damage.
Unexpectedly, D3T pre-treatment increased oxidized GSH concentrations, but decreased reduced
GSH concentrations in AGE-stressed cells. This led to testing the extent to which D3T affected
Nrf2 target genes: glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase (GR).
Therefore, in chapter 3 we provide an explanation for the D3T paradox.
In the fourth chapter of this dissertation, we present the results of studies directed at
determining the specific mechanisms for neurite retraction in SH-SY5Y cells. Study results from
previous chapters have shown that maintenance of intracellular reduced GSH was critical for
neurite protection under stressed conditions. Accumulation of oxidized GSH was associated with
greater amounts of neurite degeneration. Thus, the role of glutathionylation in driving neurite
retraction was explored. A better understanding of the mechanisms of neurite retraction can help
in the development of a targeted approach to prevention and protection against diabetic PN.
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N-ACETYLCYSTEINE CONFERS PROTECTION
AGAINST ADVANCED GLYCATION END-PRODUCT INDUCED
NEURITE RETRACTION OF SH-SY5Y CELLS VIA A
GLUTATHIONE-DEPENDENT MANNER

2.1

Abstract
N-acetylcysteine (NAC) is a commonly used thiol-containing substance widely known for

its antioxidant properties. NAC can function as an antioxidant by increasing cellular glutathione
(GSH) production, as a free radical scavenger, or a combination of these mechanisms. These
properties make NAC a compound of interest for research as a therapeutic substance for diabetic
peripheral neuropathy (PN). Diabetic PN is one of the most common complications of diabetes
and affects at least 50% of patients. Hyperglycemia-induced oxidative stress is a primary driver
in the development of PN. Peripheral nerves are particularly susceptible to oxidative stress as
they express low levels of antioxidants such as GSH. In our lab we use differentiated SH-SY5Y
cells treated with advanced glycation end products (AGE) as a model to mimic diabetic
conditions and to study the mechanisms of oxidative stress-mediated cell damage and antioxidant
protection. We have previously shown that NAC was able to completely protect against AGEinduced depletion of GSH and neurite damage. In the present study we explore the mechanisms
of NAC action on neurite protection by inhibiting GSH synthesis. Depletion of GSH resulted in
neurite retraction, even under non-stressed conditions, suggesting GSH plays a critical role in
baseline neurite maintenance. Critically, inhibition of GSH synthesis blocked all protective
effects of NAC against AGE-induced neurite damage, suggesting that the compound’s free
radical scavenging properties were not involved in neurite protection. Understanding the
mechanisms responsible for both neurite retraction and antioxidant protection can provide an
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outline for developing and/or identifying new therapeutic substances for patients with diabetic
PN.

2.2

Introduction
N-acetylcysteine (NAC) is a thiol-containing compound widely known for its potent

antioxidant properties. One of the most well-known uses for NAC is as an antidote to
acetaminophen poisoning [1]. Metabolism of acetaminophen leads to the formation of reactive
intermediate N-acetyl-p-benzoquinoneimine (NAPQI), which is cleared after conjugation with
glutathione (GSH) [2]. Once GSH is depleted, NAPQI reacts with proteins and enzymes, which
can lead to toxicity and cell death [1]. NAC protects against acetaminophen toxicity by both
increasing GSH production, and as a free radical scavenger reducing NAPQI to acetaminophen
[1,2]. These two mechanisms of NAC protection, maintenance of GSH and free radical
scavenging, have been commonly cited as conferring protection in numerous conditions and
disease states. NAC has been shown to confer protection against muscle fatigue [3,4], insulin
resistance [5], post prandial oxidative stress [6], endothelial dysfunction [6,7], T cell function in
HIV-infected individuals [8], and diabetic neuropathy [9].
The use of NAC to maintain GSH is due to its ability to provide the rate limiting
substrate of GSH synthesis, cysteine [10]. NAC is membrane permeable and does not require
active transport to be taken up, unlike cysteine [10,11]. After entering the cell NAC is
hydrolyzed to yield cysteine, increasing substrate for γ-glutamylcysteine ligase (GCL) and
allowing for increased GSH synthesis [11]. The free radical scavenging properties of NAC have
also been cited as a potential mechanism of protection in many studies and reviews [1,5–7,9,12–
16]. NAC has been shown to directly reduce the hydroxyl radical, hydrogen peroxide, and
hypochlorous acid [16], and the ability to scavenge methylglyoxal [14] and NAPQI [1].
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However, the protective effects of NAC as a free radical scavenger have predominantly been
shown in vitro [16]. This discrepancy between in vivo and in vitro studies can be largely
attributed to in vivo metabolism and low bioavailability of native NAC [13,16].
In our laboratory, we use differentiated SH-SY5Y cells stressed with advanced glycation
end products (AGE) as a model system for diabetic peripheral neuropathy (PN) [17–19].
Oxidative stress is implicated as one of the major underlying mechanisms for diabetes-induced
PN [20]. AGEs, products of non-enzymatic glycation of proteins, accumulate in circulation and
tissue in the diabetic state and are a major contributor to oxidative-stress induced complications
of diabetes, including PN [21–26]. AGE accumulation increases oxidative stress via binding to
the receptor for advanced glycation end products (RAGE) and downstream activation of NADPH
oxidase in a PKCδ-dependent manner [27,28]. The resulting increase in reactive oxygen species
(ROS) facilitates damage to peripheral nerves [21]. Peripheral nerves are particularly susceptible
to ROS, as they have low GSH levels [29], which are further depleted in diabetic conditions [9].
These characteristics of peripheral nerves led us to evaluate the effects of NAC in our model
system of PN.
Previous results from our laboratory showed that when differentiated SH-SY5Y cells were
stressed with AGEs, there was significant neurite loss [17,18]. Cells stressed with AGEs also
experienced GSH depletion, however NAC treatment was able to protect against both GSH
depletion and neurite loss [17]. Antioxidants that did not maintain GSH in the stressed (AGEtreated) condition, such as α-tocopherol and 3H-1,2-dithiole-3-thione (D3T), did not confer
protection against neurite loss [17,18]. These results led us to conclude that maintaining
intracellular GSH was critical for protection against AGE-induced neurite degeneration. In the
present studies, the mechanism of NAC protection was investigated. As was previously
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mentioned, NAC can confer protection through both its intrinsic antioxidant properties as well as
through maintenance of GSH. However, the free radical scavenging properties of NAC observed
in in vitro models have not translated to in vivo models. Consequently, the applicability of NAC
as a potential therapeutic substance for diabetic PN is highly dependent on its mechanism of
action. It was hypothesized that in our model NAC confers protection against AGE-induced
neurite degeneration via maintenance of GSH levels and not through free-radical scavenging.

2.3
2.3.1

Methods
Materials
Dulbecco’s Modified Medium (DMEM), Ham’s F12 Medium, penicillin-streptomycin,

and fetal bovine serum (FBS) were purchased from Invitrogen (Waltham, MO). All standard cell
culture flasks and plates were purchased from ThermoFisher Scientific (Waltham, MO). All
reagents such as retinoic acid, L-buthionine-sulfoximine (BSO), NAC, and reagents for GSH
analysis were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
2.3.2

Cell Culture
SH-SY5Y cells were purchased from ATCC (Manassas, VA) and were cultured initially

in growth media (DMEM, 10% FBS, 1% penicillin-streptomycin, 8 mM glucose) for 24 hours to
allow for adherence. Following adherence, growth media was replaced with differentiating
media (1:1 DMEM: F12, 1% FBS, 8 mM glucose, 10 μM retinoic acid) for five days to allow for
neuronal cell phenotype development. Treatments for all experiments took place following the
five-day differentiation period. Cells treated with NAC had .5-2 mM NAC (<1% PBS) added to
the media 24 hours prior to 5 mg/mL BSA or AGE treatment. This treatment was then
replenished in BSA and AGE treatment groups for 24 hours. For BSO-treated cells, 10-1000 μM
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BSO (< 1% PBS) was added to the media 72 hours prior to BSA or AGE treatment and
replenished during the 24-hour BSA or AGE treatment. For cells that were treated with BSO and
NAC, NAC was added concurrently with BSO. Both NAC and BSO were replenished during
BSA or AGE treatment.
2.3.3

Preparation of AGE-BSA and BSA Control
AGE-BSA was prepared as previously reported [18]. Briefly, 5 mg/ML BSA in PBS was

incubated with 33 mM glycolaldehyde dimer for 20 hours at 37°C. Control BSA was treated in
the same manner, but without the addition of glycolaldehyde. Both control and glycated BSA
were then concentrated via ammonium sulfate precipitation. Ammonium sulfate was added to
glycated BSA and control solutions (80% ammonium sulfate solution), and then centrifuged at
10,000g for 30 minutes. Precipitated proteins were resuspended with the minimal amount of PBS
required for resuspension. Solutions were then dialyzed in PBS for three days, with daily
replacement of PBS. Following dialysis, solutions were sterile filtered. The final concentrations
of both glycated and control BSA were approximately 15 mg/mL.
2.3.4

GSH Assay
Total GSH was quantified using a colorimetric based assay as described by Rahman et al.

[30]. SH-SY5Y cells were plated in 6-well plates (9 cm2) at a concentration of 0.4 x 106. Each
well was then pretreated with either NAC or vehicle (<1% PBS) for 24 hours followed by cotreatment and addition of AGE-BSA or BSA-control for an additional 24 hours. For groups
treated with BSO and NAC, NAC was added concurrently with BSO treatment. Absorption was
measured using a Bio-Tek Powerwave X200 (Winooski, VT) spectrophotometer (abs. 412nm).
All values were normalized to protein content using a BCA assay kit (Pierce, Rockford, IL).
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2.3.5

Cell Viability
Cell viability was estimated by protein content using a BCA assay kit (Pierce, Rockford,

IL). Briefly, cells were plated in 6-well plates (9 cm 2) at a concentration of .4 x 106. At time of
analysis, each well was washed three times with warm PBS (37°C) followed by harvesting with
500 μL trypsin-EDTA solution. The solution was neutralized with 500 μL growth media, and the
cell suspension was centrifuged at 1000g for 5 min. Supernatant was then discarded, and the
pellet resuspended in ice-cold PBS. This suspension was centrifuged and once again resuspended
in PBS as a rinse step. At this step, nuclei for several samples was calculated as a validation for
using protein content as an estimate for viability. Following the second PBS rinse, cells were
centrifuged and the pellet was resuspended in 250 μL extraction buffer as listed by Rahman and
colleagues [30]. To ensure complete lysis, suspensions were freeze-thawed at total of three times
in a -80°C freezer, briefly sonicated, and the centrifuged at 3000g for 5 min. Following
centrifugation, the supernatant was collected and used to measure protein content and GSH
concentrations.
2.3.6

Neurite Quantification
At the completion of experiments, photos were taken to document morphological changes

of differentiated SH-SY5Y cells. Images were captured at 10x magnification using a Zeiss Axio
Vert. A1 microscope (Oberkochen, Germany). A Zeiss AxioCam ICm1 camera was used to take
photos using Zeiss Zen2 imaging software. All images were 1388 x 1038 pixels, and exposure
time for all photos was 32.03 ms. Images were then analyzed using ImageJ (NIH) software with
NeuronJ (ImageScience) plugin. Individual neurites were traced, and neurite length was reported
as length in pixels. Neurites present in the field of view were quantified from three to four
independent experiments for each treatment group. Exclusion criteria included counting only
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neurites with clearly defined start and end locations. Neurites that were shorter than the width of
the cell body were not counted. For each treatment group, a minimum of 169 total neurites was
quantified. To quantify the impact of treatments on the longest neurites, the number of neurites
greater than or equal to the average length of neurites in the BSA control group was calculated
for each treatment group.
2.3.7

Statistical Methods
Values are presented as group means S.E.M. Treatment effects were tested using a

Student’s t-test for two variables, or analysis of variance (ANOVA) for multiple variables. A
significant ANOVA result was followed by a multiple comparisons of means test (Dunnett or
Tukey HSD), with P<0.05 considered statistically significant.

2.4
2.4.1

Results
Impact of NAC on GSH Concentrations
To establish the most effective concentration of NAC to increase total GSH levels, a dose

response was done with 0.5, 1.0, and 2.0 mM concentrations of NAC. The impact of NAC
treatment on GSH concentrations for both BSA and AGE-treated cells is shown in Figure 2.1.
Control (BSA treated) differentiated SH-SY5Y cells contained approximately 39 nmol/mg
protein of GSH. As expected, AGE-treated cells experienced a significant drop in GSH (~18.3
nmol/mg protein). 1 mM NAC treatment in BSA-treated cells resulted in the highest GSH levels,
however 2 mM NAC treatment did not increase GSH levels above BSA control (Fig. 2.1). NAC
did not significantly increase [GSH] at any concentration when cells were treated with AGE,
however a trend towards an increase was observed at 1 and 2 mM NAC concentrations (Fig.
2.1). Based on these initial results, 1 mM NAC was chosen as the optimal concentration for
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further experiments. The effect of 1 mM NAC treatment on GSH levels of AGE-treated cells was
revaluated and follow up experiments showed that 1 mM NAC treatment significantly increased
GSH (Fig. 2.2).
2.4.2

The Effect of 1 mM NAC on Protection Against AGE-Induced Neurite Loss
Previously in our laboratory, we were able to show that 2 mM NAC treatment was able to

completely protect against AGE-induced neurite loss [17]. In our current studies, we have shown
that 1 mM NAC treatment resulted in the highest levels of intracellular [GSH] in BSA-treated
SH-SY5Y cells. Furthermore, 1 mM NAC treatment significantly increased GSH in AGE-treated
cells. To assess the effects of NAC in AGE-mediated neurite degeneration, the following
functional outcomes were analyzed: neurite length and average number of long neurites per field
of view. Consistent with our previous work, AGE treatment significantly compromised neurite
morphology as measured by neurite length (Fig. 2.3) and the average number of long neurites per
field of view (Fig 2.4). NAC (1 mM) conferred protection against AGE-mediated decrease in
neurite length (Fig. 2.3) and loss of long neurites (Fig. 2.4).
2.4.3

BSO Does Response for Depletion of Intracellular GSH
To confirm whether NAC confers protection via its GSH maintaining properties,

inhibition of GSH synthesis was required. BSO at concentrations of 10, 100, and 1000 μM was
added to media for 72 hours following differentiation. 100 μM BSO led to near complete
depletion of GSH, and 1000 μM BSO treatment fell below the level of detection (Fig. 2.5). A 72hour treatment of 1000 μM BSO was determined to be optimum for complete GSH depletion in
differentiated SH-SY5Y cells.
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2.4.4

The Effect of BSO Treatment on Control SH-SY5Y Cells
While establishing the dose response for BSO-induced GSH depletion, it was noted that

there were also changes in cell morphology with BSO treatment. Treatment of SH-SY5Y cells
with 1000 μM BSO resulted in a decrease in neurite length (Fig. 2.6). Co-treatment of cells with
both BSO and 2 mM NAC protected neurite morphology, however 1 mM NAC co-treatment did
not confer protection (Fig. 2.6). No significant differences among groups were observed for
number of long neurites, but trends were similar (Fig. 2.7). Representative photos of each group
are shown in figure 2.8. BSO (1000 μM) also significantly decreased viability, and both 1 and 2
mM NAC co-treatment conferred partial protection (Fig. 2.9). Co-treatment of cells with 1000
μM BSO and NAC had a very minor impact on intracellular GSH (~0.6 and 0.3 nmol/mg for 1
mM and 2 mM NAC, respectively), suggesting NAC protection was not GSH-dependent (Fig.
2.10).
2.4.5

The Effect of BSO Treatment on AGE-treated SH-SY5Y Cells
Depletion of intracellular GSH followed by AGE treatment led to a complete loss of

neurites in SH-SY5Y cells (Figs. 2.11, 2.12, 2.13). Only SH-SY5Y cells treated with vehicle (no
BSO) for 3 days followed by AGE treatment had quantifiable neurites (Fig. 2.12 & 2.13). BSO
(1000 μM) completely depleted GSH (~0-.003 nmol/mg protein) in all groups (Fig. 2.14), and
NAC conferred no protection against either AGE or AGE-BSO-induced loss of viability (Fig.
2.15). When GSH synthesis was inhibited with BSO, NAC did not confer protection against
AGE-mediated neurite damage, decrease in viability, and loss of GSH.
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2.5

Discussion
Hyperglycemia induced oxidative stress is a major source of damage to peripheral

neurons in diabetic patients [31]. Therefore, understanding mechanisms leading to the protection
and maintenance of endogenous antioxidants, such as GSH, is the first step to discovery of novel
therapeutic treatments and/or substances. In this study, we confirmed previous results from our
laboratory showing that NAC confers complete protection against AGE-induced neurite
retraction in differentiated SH-SY5Y cells. Analysis of changes to neurite morphology was done
by quantifying the length of neurites in each treatment group as well as the total number of
neurites that exceeded the average length of the control group. This method was developed to
quantify the retraction of neurites that was observed when cells were exposed to a stressed
condition. The analysis of long neurites was particularly important as diabetic neuropathy
commonly presents in a “stocking-glove” distribution, where the longest neurons are damaged
first, leading to sensory and motor nerve dysfunction in the extremities [31,32].
In previous studies, we have shown that AGE treatment results in a significant increase in
NADPH oxidase-mediated ROS generation [18], and that NAC treatment confers protection
against AGE-induced depletion of GSH, DNA oxidation, and protein carbonyl formation [17].
Importantly, only antioxidants that maintained GSH were able to protect against AGE-induced
neurite degeneration [17,18]. GSH plays a critical role in protection against ROS and oxidative
stress in neurons [33] via multiple mechanisms including its role in maintaining redox status and
reduced thiols [34–37], direct interaction with ROS [38], and working synergistically with other
antioxidants as part of the endogenous antioxidant defense system (Fig. 2.16) [38]. In our model,
NAC treatment clearly results in increased concentrations of GSH in both control and AGEtreated cells. However, it was possible that NAC conferred protection through its intrinsic
antioxidant properties as well as through maintenance/protection of GSH.

64
To determine whether intrinsic antioxidant properties of NAC were responsible for the
protection observed, we inhibited GSH synthesis. GSH synthesis was inhibited using BSO, a
specific inhibitor of GCL [39]. GCL is the first, and rate limiting, enzyme in GSH synthesis with
inhibition resulting in GSH depletion [40]. BSO (1000 μM) treatment for 72 hours resulted in
complete GSH depletion in differentiated SH-SY5Y cells. GSH depletion alone led to
significantly decreased viability, neurite length, and trended towards loss of long neurites
(p=.053) demonstrating that GSH plays a critical role in maintenance of neurites in SH-SY5Y
cells. To test whether NAC could confer protection against BSO-induced damage, cells were cotreated with BSO and 1-2 mM NAC. Both concentrations of NAC conferred partial protection
against BSO-induced viability loss, but only 2 mM NAC protected neurite morphology. These
results suggest that NAC, particularly at higher concentrations, can confer protection via a nonGSH mediated mechanism.
Non-GSH mediated protection of NAC was observed under control conditions (no AGE
stress) against BSO-induced neurite retraction. However, NAC did not confer any protection
against AGE-treated SH-SY5Y cells that were depleted of GSH. The combination of GSH
depletion followed by AGE-induced stress resulted in a complete loss of neurites and dramatic
loss in viability. Again, NAC conferred no protection under these conditions. We had previously
shown that NAC was able to confer complete protection against AGE-induced viability loss [17],
and in this study we have shown that NAC also confers complete protection against AGEinduced neurite damage. That NAC loses the entirety of its protective effect upon inhibition of
GSH synthesis is strong evidence that NAC confers protection against AGE-induced neurite
damage via a GSH-mediated mechanism.
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Bioavailability of native NAC in humans is low due to intestinal deacetylation (oral
formulation) and first-pass metabolism, and by deacetylation in the liver (oral and intravenous
formulation) [16,41]. Therefore, the protective effects of NAC that are due to its intrinsic
antioxidant properties observed in in vitro studies may not translate in in vivo models. In
agreement with our results, NAC has been shown to confer protection in in vivo models against
peripheral nerve injury. Intraperitoneal injection of NAC in rats conferred protection against
chronic constriction injury-induced mechanical, thermal, and cold allodynia [33]. In another rat
model, sciatic nerve axotomy induced a 21% loss of neurons in the axotomized ganglia. Rats
treated with intravenous NAC post-operatively experienced near complete protection of neurons
in the axotomized ganglia, with only a 3% loss of neurons [42]. In a long-term study of diabetic
neuropathy in rats, seven weeks of oral administration of NAC in diabetic animals conferred
significant protection against diabetes-induced thermal hyperalgesia and motor deficits. Analysis
of the sciatic nerve showed that diabetic animals experienced depletion of GSH and protein
thiols, however NAC-treated diabetic animals did not differ from controls [9].
In our study we have shown that GSH is critical for the maintenance of neurites, as
simple inhibition of GSH synthesis leads to neurite retraction. We have also shown that NAC
confers protection against AGE-induced neurite damage via an exclusively GSH-mediated
mechanism. Future studies will focus on evaluating the effectiveness of other GSH-inducing
substances, identifying the mechanisms of neurite retraction, and identifying why GSH is critical
for neurite protection.
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Figure 2.1 Effect of NAC pre-treatment on GSH concentrations of BSA- and AGE-treated SHSY5Y cells.
Differentiated cells were treated with vehicle, 0.5, 1, and 2 mM NAC for 24 hours prior to BSA
or AGE treatment. Cells were treated with 5 mg/mL BSA or AGE for 24 hours with
replenishment of NAC treatment. GSH concentrations were normalized to total protein. Data
were analyzed by one-way ANOVA with Dunnett’s post-hoc analysis from 3 independent
experiments. Data points with an * are significantly different (p < 0.05) from the vehicle treated
BSA group.
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Figure 2.2 NAC (1 mM) pre-treatment protects against AGE-induced GSH depletion.
Differentiated cells were treated with 1 mM NAC 24 hours prior to a 24-hour 5 mg/mL AGE
treatment. NAC (1 mM) was replenished during the 24-hour AGE treatment. GSH
concentrations were normalized to total protein. Data were analyzed via 2-tailed unpaired
Student’s t-test from 3 independent experiments. Bars with an * are significantly different (p <
0.05) from the control group.
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Figure 2.3 NAC pre-treatment confers complete protection against AGE-induced neurite
retraction.
Differentiated cells were treated with 1 mM NAC 24 hours prior to 5 mg/mL BSA or AGE
treatment. NAC (1 mM) was replenished during the 24-hour BSA and AGE treatments. Data
were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 6 independent
experiments. At least 190 neurites were analyzed per treatment group. Bars with superscript
letters different from each other are significantly different (p < 0.05).
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Figure 2.4 NAC pre-treatment confers complete protection against AGE-induced long neurite
loss.
Differentiated cells were treated with 1 mM NAC 24 hours prior to 5 mg/mL BSA or AGE
treatment. NAC (1 mM) was replenished during the 24-hour BSA and AGE treatments. Data
were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 6 independent
experiments. At least 190 neurites were analyzed per treatment group. Bars with superscript
letters different from each other are significantly different (p < 0.05).
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Figure 2.5 BSO (1000 μM) treatment results in depletion of cellular GSH.
Following differentiation, 10, 100, and 1000 μM BSO was added to the media for 72 hours. BSA
and AGE groups were treated with 5 mg/mL BSA or AGE, respectively, for 24 hours following
differentiation. GSH concentrations were normalized to total protein. Data were analyzed by
one-way ANOVA with Tukey’s post-hoc analysis from 3-6 independent experiments. Bars with
superscript letters different from each other are significantly different (p < 0.05).
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Figure 2.6 BSO treatment induces neurite loss and 2 mM NAC pre-treatment confers protection.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL BSA was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Dunnett’s post-hoc analysis from 4
independent experiments. At least 170 neurites were analyzed per treatment group. Bars with an
* are significantly different (p < 0.05) from the BSA BSO group.
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Figure 2.7 BSO treatment has no significant impact on number of long neurites
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL BSA was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 4
independent experiments. At least 170 neurites were analyzed per treatment group. Bars with
superscript letters different from each other are significantly different (p < 0.05).
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Figure 2.8 BSO treatment induces neurite loss and 2 mM NAC confers protection.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL BSA was added along with replenishment of BSO and
NAC. Images are representative samples of each treatment group and are captured at 10X.
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Figure 2.9 BSO treatment decreases viability and NAC pre-treatment confers partial protection.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL BSA was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 3
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 2.10 NAC does not restore GSH with BSO treatment.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL BSA was added along with replenishment of BSO and
NAC. GSH concentrations were normalized to total protein. Data were analyzed by one-way
ANOVA with Tukey’s post-hoc analysis from 3 independent experiments. Bars not joined by a
common superscript letter are significantly different from each other (p < 0.05).
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Figure 2.11 NAC does not confer protection against AGE-induced neurite retraction following
BSO treatment.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL AGE was added along with replenishment of BSO and
NAC. Images are representative samples of each treatment group and are captured at 10X.
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Figure 2.12 NAC does not confer protection against AGE-induced neurite retraction following
BSO treatment.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL AGE was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 4
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 2.13 NAC does not confer protection against AGE-induced long neurite loss following
BSO treatment.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL AGE was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 4
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 2.14 NAC pre-treatment does not restore GSH after AGE-BSO treatment.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL AGE was added along with replenishment of BSO and
NAC. GSH concentrations were normalized to total protein. Data were analyzed by one-way
ANOVA with Tukey’s post-hoc analysis from 3 independent experiments. Bars with superscript
letters different from each other are significantly different (p < 0.05).
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Figure 2.15 NAC does not confer protection against AGE-BSO-induced viability loss.
Following differentiation, 1000 μM BSO was added to media for 72 hours with 1-2 mM NAC.
After the 72-hour treatment, 5 mg/mL AGE was added along with replenishment of BSO and
NAC. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 3
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 2.16 Synergistic role of GSH in the endogenous antioxidant defense system.
Lipid (LH); lipid peroxyl radical (LOO.); lipid hydroperoxide (LOOH); α-tocopherol (Vit E);
tocopheryl radical (Vit E°); ascorbate (ASC); ascorbate free radical (AFR); glucose-6-phosphate
dehydrogenase (G6PD); glucose-6-phosphate (G6P); 6-phosphogluconate (6-PGA); glutathione
reductase (GR); glutathione peroxidase (GPX); superoxide dismutase (SOD). Vit E reduces
reactive LOO. to LOOH to protect/prevent against a chain reaction of phospholipid fatty acid
oxidation. This process generates Vit E°, which is then reduced back to Vit E by ASC. ASC is
maintained in its reduced state by a GSH-dependent enzymatic reaction. GPX reduces hydrogen
peroxide at the expense of GSH. Pro-oxidative conditions will lead to depletion of GSH and a
buildup of GSSG. GR reduces GSSG to GSH at the expense of NADPH. G6PD is the major
cellular generator of NADPH.
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D3T POTENTIATES ADVANCED GLYCATION END
PRODUCT INDUCED OXIDATIVE STRESS IN A CELL CULTURE
MODEL OF DIABETIC PERIPHERAL NEUROPATHY

3.1

Abstract
Diabetes mellitus is one of the most common chronic diseases and peripheral neuropathy

(PN) affects at least 50% of diabetic patients. Medications available for patients ameliorate
symptoms (pain), but do not protect against cellular damage and come with severe side effects
leading to discontinued use. In our lab we use differentiated SH-SY5Y cells treated with
advanced glycation end products (AGE) as a model to mimic diabetic conditions and to study the
mechanisms of oxidative stress (OS) mediated cell damage and antioxidant protection. Nacetylcysteine (NAC), a common supplement, was previously shown in our lab to fully protect
against AGE-induced damage. Our lab has also shown that 3H-1,2-dithiole-3-thione (D3T), a
cruciferous vegetable constituent and potent inducer of nuclear factor (erythroid-derived 2)- like
(Nrf2), can significantly increase cellular GSH concentrations and protect against H 2O2–induced
cell death. Paradoxically, D3T conferred no protection against AGE-induced cell death or neurite
degeneration. In the present study we show that D3T in combination with AGE increased
reactive oxygen species (ROS) generation, depleted GSH, and increased glucose-6-phosphate
dehydrogenase (G6PD) expression, suggesting its role as an NADPH generating agent may
promote OS rather than provide protection under these conditions. D3T further contributed to
depletion of GSH in combination with AGE challenge by significantly depressing glutathione
reductase activity. Inhibition of NADPH generation via G6PD, the protein product of a Nrf2responsive gene, with dehydroepiandrosterone was found to protect against AGE-induced ROS
generation, loss of viability, and neurite degeneration. These results suggest that using a strategy
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to protect against oxidative stress by upregulation of the endogenous antioxidant defense system
via Nrf2 may backfire and promote further damage if the products of upregulation contribute to
ROS generation.

3.2

Introduction
Diabetes mellitus, a disease hallmarked by hyperglycemia, is one of the most common

chronic diseases worldwide with new diagnoses on an upward trajectory. By some estimates,
30.3 million Americans live with diabetes[1]. The high incidence of diabetes poses both a public
health as well as a financial concern. Direct annual medical costs for diabetes treatment in recent
years has reached $176 billion[2]. Therefore, there has been growing interest in identifying new
and easily accessible preventive compounds that may alleviate diabetic health complications.
Peripheral neuropathy (PN) is one of the most common health complications in type 1
and 2 diabetics, with oxidative stress implicated as a major contributor to diabetes-induced
PN[3]. An underlying cause of oxidative stress-induced complications in diabetes, including PN,
is the accumulation of Advanced Glycation End Products (AGEs) in circulation and tissues [4–
8]. The products of non-enzymatic glycation of proteins, AGEs accumulate in peripheral nerves
of diabetic patients [9]. Through binding the receptor for AGE (RAGE) in target tissues, AGEs
stimulate oxidative stress through downstream activation of NADPH oxidase in a PKCδdependent manner [10,11]. The resulting increase in reactive oxygen species (ROS) facilitates
damage in peripheral neurons [4]. Given the above mechanism of AGE-induced PN, dietary
compounds with antioxidant properties have been proposed as potential remediating agents.
Dietary compounds with antioxidant properties may provide benefit through a variety of
mechanisms [12–14]. Some compounds including ascorbate, N-acetylcysteine (NAC) or alphatocopherol have intrinsic antioxidant potential. These compounds can either directly neutralize
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ROS and free radicals, or in the case of NAC, provide the necessary substrate for synthesis of
essential cellular antioxidants such as glutathione (GSH). Other compounds, including 3H-1,2dithiole-3-thione (D3T), generate an antioxidant effect through stimulating endogenous cellular
antioxidant defenses. In the case of D3T, the antioxidant response involves activation of Nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) through several potential mechanisms [15–18]. Nrf2, a
transcription factor, controls expression of a wide array of target genes including glutathione
synthesizing enzymes, quinone reductases, glutathione reductase (GR), as well as NADPH
generating enzymes such as glucose-6-phosphate dehydrogenase (G6PD) [14,19–21]. Reduced
NADPH resulting from G6PD upregulation serves as a cofactor for GR mediated recycling of
oxidized glutathione (GSSG) back to its reduced form (GSH). However, NADPH oxidases (a
major source of AGE-induced oxidative stress) [4,9] may also potentially utilize reduced
NADPH generated through Nrf2 activation to increase ROS production, stressing the importance
of mechanistic context when assessing the benefit of individual antioxidant and phytochemical
compounds.
The variable mechanism of action of different antioxidants suggests some compounds
may be more suitable than others in protection against diabetic PN. In particular, previous studies
from our laboratory demonstrated variable effects of antioxidant compounds on AGE-induced
oxidative stress and neurite morphology in the differentiated SH-SY5Y cell model. NAC offered
protection from neurite loss as well as protection from DNA and protein oxidation [22]. On the
other hand, D3T, a potent Nrf2 inducer, had a paradoxical impact on redox balance in SH-SY5Y
cells exposed to AGE. D3T co-treatment promoted AGE-induced ROS formation, did not
maintain GSH levels (compared to BSA control group), and did not protect from AGE-induced
neurite loss [23]. In the present studies, the mechanism underlying D3T’s paradoxical effect on
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oxidative stress in the presence of AGEs was investigated. It was hypothesized that D3T
mediated induction of NADPH generating antioxidant enzyme G6PD promotes AGE-induced
oxidative damage.

3.3
3.3.1

Methods
Materials
Dulbecco’s Modified Medium (DMEM), Ham’s F12 Medium, penicillin-streptomycin,

and fetal bovine serum (FBS) were purchased from Invitrogen (Waltham, MO). All standard cell
culture flasks and plates were purchased from ThermoFisher Scientific (Waltham, MO). Black
24-well culture plates for fluorescence analysis were purchased from Cellvis (Sunnyvale, CA).
All reagents such as retinoic acid (RA), dehydroepiandrosterone (DHEA), bovine serum albumin
(BSA), NAC, D3T, and reagents for GSH, ROS, and GR activity analysis were purchased from
Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
3.3.2

Cell Culture
SH-SY5Y cells were purchased from ATCC (Manassas, VA) and were cultured initially

in growth media (DMEM, 10% FBS, 1% penicillin-streptomycin, 8 mM glucose) for 24 hours to
allow for adherence. Following adherence, growth media was replaced with differentiating
media (1:1 DMEM: F12, 1% FBS, 8 mM glucose, 10 μM retinoic acid) for five days to allow for
neuronal cell phenotype development. Treatments for all experiments took place following the
five-day differentiation period. Cells treated with NAC or D3T had 1 mM NAC (<1% PBS) or
100 μM D3T (<1% DMSO) added to the media 24 hours prior to 5 mg/mL BSA or AGE
treatment. This treatment was then replenished in BSA and AGE treatment groups for 24 hours.
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For DHEA treated cells, 100 μM DHEA (< 1% DMSO) was added to the media 24 hours prior to
BSA or AGE treatment and replenished during the 24-hour BSA or AGE treatment.
3.3.3

Preparation of AGE-BSA and BSA Concentration
AGE-BSA was prepared as was previously reported in our lab [23]. Briefly, 5 mg/mL

BSA in PBS was incubated with 33 mM glycolaldehyde dimer for 20 hours at 37°C. Control
BSA was treated in the same manner, but without the addition of glycolaldehyde. Both control
and glycated BSA were then concentrated via ammonium sulfate precipitation. Ammonium
sulfate was added to glycated BSA and control solutions (80% ammonium sulfate solution), and
then centrifuged at 10,000g for 30 minutes. Precipitated proteins were resuspended with the
minimal amount of PBS required for resuspension. Solutions were then dialyzed in PBS for three
days, with daily replacement of PBS. Following dialysis, solutions were sterile filtered. The final
concentrations of both glycated and control BSA were approximately 15 mg/mL.
3.3.4

GSH Assay
Reduced GSH, as well as its oxidized form GSSG, were quantified using a colorimetric

based assay as described by Rahman et al. [24]. SH-SY5Y cells were plated in 6-well plates (9
cm2) at a concentration of .4 x 106. Each well was then pretreated with either NAC, D3T, or
vehicle (<1% DMSO or PBS) for 24 hours followed by co-treatment and addition of AGE-BSA
or BSA-control for an additional 24 hours. Absorption was measured using a Bio-Tek
Powerwave X200 (Winooski, VT) spectrophotometer (abs. 412nm). All values were normalized
to protein content using a BCA assay kit (Pierce, Rockford, IL).

94
3.3.5

ROS Assay
ROS assay was conducted as described previously[25]. Briefly, SH-SY5Y cells were

plated on black coated 24-well plates (1.9 cm2) at a concentration of .08 x 106/cm2. After
differentiation, each well was pre-treated with indicated compounds for 24 hours. followed by an
additional 24-hour co-treatment and addition of either AGEs or BSA control. At the end of 48
hours, media was gently removed and 200 μl of 20 μM 2′,7′-dichlorofluorescin diacetate
(DCFH-DA) in PBS was added to each well. Intracellular ROS was measured after a 20-minute
incubation at 37C and 5% CO2 using a Synergy H1 Multi-Mode Reader (ex/em. 485/530).
Fluorescence units were further normalized to viable cell number using a 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, St. Louis, MO).
3.3.6

Glutathione Reductase Activity
GR activity was measured as described by Mannervik [26]. Briefly, SH-SY5Y cells were

plated in 6-well plates (9 cm2) at a concentration of .4 x 106. Each well was then pretreated with
either NAC, D3T, or vehicle (<1% DMSO or PBS) for 24 hours followed by co-treatment and
addition of AGE-BSA or BSA-control for an additional 24 hours. Absorption was measured
using an Agilent Cary 60 (Santa Clara, CA) spectrophotometer (abs. 340 nm) at 30°C over a
five-minute period. Activity for each sample was normalized to total DNA. DNA content was
measured with 1μL of sample using a Thermo Scientific NanoDrop 2000 (Waltham, MA)
spectrophotometer (abs. 260 & 280 nm). Activity is reported as % of BSA control.
3.3.7

Cell Viability Assay
Cell viability was assessed after indicated treatment and duration using MTT, according

to the manufacturer's instructions. Briefly, SH-SY5Y cells were plated and differentiated in 24well plates. At the end of the specified time point, cell media was removed and replaced with
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serum free media containing 500ug/mL MTT. Cells were incubated for 2 hours. Formazan
product was dissolved using DMSO and quantified using Bio-Tek Powerwave X200
spectrophotometer (abs. 540nm).
3.3.8

Western Blotting
All Western blots were run using a Mini-PROTEAN Tetra Cell system (Bio-rad,

Hercules, CA). Both 10% and 4-20% gradient polyacrylamide gels were used. For gel
electrophoresis, the running buffer was made up of 25 mM Tris, 192 mM glycine, and .1% (w/v)
SDS at pH 8.3. Gels were run at constant voltage (200v) for 30-50 minutes. For protein transfer
to nitrocellulose membranes, transfer buffer was made up of 25 mM Tris, .2 M glycine, and 20%
methanol at pH 8.5. A constant voltage (90v) for 60 minutes was maintained for transfers. The
transfer buffer was refrigerated prior to use, and the entire apparatus was kept cold (approx. 4°C)
during protein transfer. Following transfer, blots were incubated based on antibody manufacturer
recommendations. For G6PD, GR, and β-actin quantification, blots were incubated for 12 hours
on a plate shaker at 4°C with a polyclonal rabbit antibody (1:1000) (Cell Signaling, Danvers,
MA) for G6PD, monoclonal mouse antibody (2 μg/mL) (Sigma-Aldrich, St. Louis, MO) for GR,
and monoclonal rabbit (1:1000) (Cell Signaling, Danvers, MA) for β-actin. Both anti-rabbit and
anti-mouse secondary antibodies (1:1000) were HRP-linked, and an HRP-detection kit followed
by photo-development was used (Cell Signaling, Danvers, MA). All G6PD and GR bands were
normalized to their corresponding β-actin bands and results reported as % of β-actin.
3.3.9

Neurite Quantification
At the completion of experiments, photos were taken to document morphological changes

of differentiated SH-SY5Y cells. Images were captured at 10x magnification using a Zeiss Axio
Vert. A1 microscope (Oberkochen, Germany). A Zeiss AxioCam ICm1 camera was used to take
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photos using Zeiss Zen2 imaging software. All images were 1388 x 1038 pixels, and exposure
time for all photos was 32.03 ms. Images were then analyzed using ImageJ (NIH) software with
NeuronJ (ImageScience) plugin. Individual neurites were traced, and neurite length was reported
as length in pixels. Neurites present in the field of view were quantified from three to four
independent experiments for each treatment group. Exclusion criteria included counting only
neurites with clearly defined start and end locations. Neurites that were shorter than the width of
the cell body were not counted. For each treatment group, a minimum of 100 total neurites was
quantified. To quantify the impact of treatments on the longest neurites, the number of neurites
greater than or equal to the average length of neurites in the BSA control group (115 pixels) was
calculated for each treatment group.
3.3.10 Statistical Methods
Values are presented as mean S.E.M. Comparison of means was conducted using
analysis of variance (ANOVA) followed by multiple comparisons of means (Dunnett or Tukey
HSD), with P<0.05 considered statistically significant.

3.4
3.4.1

Results
Impact of D3T and NAC on GSH status
Previously, Pazdro and Burgess demonstrated that both NAC and D3T increase total

GSH in the absence of AGEs, while only NAC exerted a protective effect on GSH in the
presence of AGEs [22,23]. To further evaluate this variable effect in SH-SY5Y cells, reduced
GSH and its oxidized form GSSG were measured in cells treated with NAC or D3T and AGE
challenge or BSA control. Both NAC and D3T significantly increased total GSH in BSA and
AGE groups (Fig. 3.1). In addition, NAC and D3T increased reduced GSH levels by 241% and
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444%, respectively (Fig. 3.2). Importantly, D3T treatment significantly increased reduced GSH
in the absence of AGEs to a greater extent than NAC. This is consistent with the mechanism of
action of D3T through Nrf2 induction, where both GSH synthesis and NADPH-dependent
recycling of GSSG via GR are upregulated [27]. Hence reduced GSH, in response to D3T, is
increased not only through increased synthesis, but also through increased recycling of oxidized
GSSG back to its reduced form. In contrast, NAC provides antioxidant protection primarily
through providing cysteine as substrate for GSH synthesis [28], independent of NADPHmediated recycling of GSSG. Consistent with this mechanism, GSSG levels were upregulated in
the absence of AGE with NAC treatment while D3T treatment did not significantly increase
GSSG under the same conditions (Fig. 3.3). When challenged with AGE, D3T treated SH-S5Y5
cells showed no significant increase in GSH (Fig. 3.2) but a drastic increase in GSSG (Fig. 3.3),
showing a pro-oxidative effect of D3T specific to AGE challenge conditions. The 3-fold increase
in GSSG with D3T treatment (compared to AGE control group) suggests that GR-mediated
recycling of GSSG back to GSH may be impaired under AGE-D3T treated conditions. NAC
treatment, on the other hand demonstrated a significant increase in both reduced GSH and GSSG
in the presence of AGEs, consistent with AGE-mediated pro-oxidative effect and the protective
role of NAC (Fig. 3.2 & 3.3).
3.4.2

Impact of D3T on Cell Viability and ROS Generation
To further assess the paradoxical effect of D3T upon AGE treatment, cell viability after

vehicle or D3T and AGE challenge was assessed. SH-SY5Y cells treated with AGEs alone had a
significant decrease in cell viability (Fig. 3.4). While D3T had no effect on cell viability in the
absence of AGEs, treatment of SH-SY5Y cells with AGEs and D3T resulted in a potentiated
effect of AGEs on decreased cell viability (Fig. 3.4). Intracellular ROS levels were further

98
measured to specifically investigate the potentiation effect of D3T on AGE-induced oxidative
stress. Consistent with cell viability data, AGE treatment alone significantly increased
intracellular ROS while D3T treatment amplified that effect (Fig. 3.5).
3.4.3

The Effect of D3T on G6PD
Given the potentiation effect of D3T on AGE-induced oxidative stress, and the

mechanism of action of AGE through activation of NADPH oxidase, it was hypothesized that
D3T promotes AGE-induced oxidative stress through increased generation of reduced NADPH.
G6PD, the rate-limiting enzyme of the pentose phosphate pathway, is one of the major
contributors to the cellular reduced NADPH pool. It is further a Nrf2 target gene, suggesting that
D3T may upregulate G6PD via its Nrf2-mediated mechanism of action. To assess the effect of
D3T on G6PD, G6PD protein expression was measured after a D3T treatment in AGE challenge
or BSA control conditions. D3T significantly increased G6PD protein expression under BSA
control conditions. Interestingly, AGE treatment alone also upregulated G6PD expression
relative to BSA-control. Finally, D3T and AGE treatment demonstrated an additive effect on
G6PD expression (Fig. 3.6). These findings were consistent with the hypothesis that D3T
potentiates AGE-induced oxidative stress via increased G6PD-mediated generation of NADPH
that feeds NADPH oxidase and sustains its generation of ROS.
3.4.4

The effect of D3T on Glutathione Reductase
Reducing potential generated by G6PD in the form of NADPH may be utilized by

NADPH oxidase or GR, among other enzymes. The potentiation impact of D3T on AGEinduced oxidative stress may therefore result from both upregulating NADPH generation as well
as hindering other enzymes that would normally utilize NADPH. To explore this possibility, the
impact of D3T treatment on GR was investigated, since GR is a major NADPH utilizing enzyme
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in the context of antioxidant defense. D3T treatment under BSA control conditions increased GR
protein expression (Fig. 3.7), likely due to its Nrf2 inducing properties and consistent with the
profound increase in reduced GSH resulting from D3T treatment in the absence of AGEs. AGE
treatment alone also increased GR protein expression, and co-treatment with D3T resulted in no
further change (Fig. 3.7). Interestingly, GR activity did not correlate with protein expression in
cells challenged with AGE and treated with D3T. In this scenario, D3T treatment unexpectedly
resulted in a significant decrease in GR activity (Fig. 3.8). The impact of D3T on GR activity
under AGE challenge conditions sheds further light on the mechanism for the D3T paradox.
Upregulation of G6PD via D3T helps explain the mechanism for increased ROS generation
under AGE challenge, but theoretically this mechanism would also provide more reducing
equivalents for GR to maintain GSH. Therefore, the increase in GSSG (3-fold) between AGE
and AGE-D3T groups remained perplexing. Our data provide an answer for this apparent
disconnect. Treatment with D3T under AGE challenge conditions not only exacerbates ROS
generation, but also disrupts GR activity, a critical enzyme necessary for maintaining redox
balance, leaving the cells highly susceptible to oxidative damage.
3.4.5

The Effect of DHEA on Cell Viability and ROS Generation
To test the relationship between G6PD and oxidative stress under AGE treatment, DHEA

was utilized. DHEA is an uncompetitive inhibitor of G6PD [29]. Treatment of SH-SY5Y cells
with AGEs in the presence of DHEA reversed the effect of AGEs on ROS (Fig. 3.9).
Furthermore, DHEA treatment reversed the effect of D3T on potentiating AGE-induced ROS.
Cell viability was additionally measured in response to D3T and AGE treatment in the presence
or absence of DHEA. As confirmed previously (Fig. 3.3), D3T potentiated the effect of AGE on
cell viability (Fig. 3.10). Co-treatment with DHEA rescued SH-SY5Y cells from AGE-induced
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and AGE-D3T-induced decrease in cell viability (Fig. 3.10). Collectively these studies confirmed
the importance of G6PD in AGE-induced oxidative stress. They further implicated G6PD in the
potentiation effect of D3T on the pro-oxidative outcomes of AGE treatment.
3.4.6

The Effect of DHEA on Neurite Morphology
To assess the importance of G6PD in AGE-mediated neurite functional outcomes, neurite

length and average number of neurites per field of view were analyzed in the presence and
absence of DHEA. Consistent with previous studies, AGE treatment compromised neurite
morphology as measured by average neurite length (Fig. 3.11) and average neurite number per
field of view (Fig. 3.12). While D3T did not further potentiate the effect of AGE on neurite
morphology, it is possible a ceiling effect was approached with AGE treatment alone.
Interestingly, inhibition of G6PD via DHEA rescued SH-SY5Y cells from AGE-induced neurite
damage (Figs. 3.11-3.13), demonstrating the importance of G6PD-mediated generation of
NADPH in the AGE-mediated mechanism of PN.

3.5

Discussion
In the diabetic state there is a significant increase AGE synthesis, as well as AGE

accumulation in peripheral nerves [5,9]. To elucidate the mechanism of action of the AGERAGE axis, the Vincent et al. group isolated dorsal root ganglia (DRG) from Sprague Dawley
rats. RAGE was shown to be localized throughout the entire neurons, and neurons that were
treated with the RAGE ligand S100 had a significant increase in ROS generation. Inhibition of
RAGE with an antibody led to near complete inhibition of S100 induced ROS generation, thus
further establishing the importance of AGE-RAGE interaction in ROS generation[4]. Our
laboratory has focused on this pathway and strategies to ameliorate the effects of excess ROS
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production in differentiated SH-SY5Y cells. It was found that RAGE is abundantly expressed in
differentiated SY-SY5Y cells and that multiple treatments do not impact protein expression (data
not shown).
The present studies evaluated the mechanisms responsible for the potentiation effect of
D3T on AGE-induced oxidative stress. Pazdro and Burgess have previously shown that
treatment with NAC was able to protect both viability and morphology of SH-SY5Y cells
stressed with AGEs [22]. It was hypothesized that NAC conferred protection by maintaining
intracellular GSH. However, treating with D3T led to potentiation of damage under AGE stress
even though under control conditions a significant increase in GSH was observed [23]. The
critical observation from the Pazdro and Burgess study, that D3T potentiated ROS generation
only under AGE-challenged conditions, led us to explore this mechanism in greater detail.
G6PD emerged as a key enzyme responsible for D3T-mediated potentiation of oxidative
stress induced by AGEs, due to its role as a major generator of NADPH. Depending on context,
increased expression and activity of G6PD has been shown to increase NADPH concentration
and NADPH oxidase-mediated superoxide generation [30]. In our cell culture model, oxidative
stress is induced by AGE-mediated activation of NADPH oxidase [22,23], and hence an increase
in NADPH concentration would provide more reducing equivalents for superoxide generation.
Furthermore, D3T has been shown to be a potent Nrf2 inducer [31] and G6PD is a Nrf2
responsive gene [32]. By inhibiting G6PD with DHEA, we were able to completely reverse both
the effect of AGE and AGE-D3T treatment on ROS generation, viability, and morphology.
These data bring to light the critical role of G6PD in AGE-mediated ROS generation and add
further complexity to the relationship between oxidative stress and endogenous antioxidant
defenses.
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Traditionally, Nrf2 activation is expected to protect against oxidative stress through its
coordinated regulation of metabolic and antioxidant enzyme expression. In particular, the
downstream upregulation of pentose phosphate pathway enzymes is critical for production of
NADPH to maintain antioxidants such as GSH, thioredoxin, and glutaredoxin [33]. In the liver,
the major detoxification organ, Nrf2-null mice are prone to oxidative stress induced liver injury
[34]. Keap1-hepatocyte knockout mice (Keap1-HKO), a model for increased liver Nrf2
activation, have been shown to be more resistant to acetaminophen hepatotoxicity [35]. Keap1HKO mice had significantly higher G6PD mRNA expression which corresponded to a
significant increase in liver NADPH concentration [19]. These observations suggest that Nrf2induced increase in NADPH generation enzymes lead to protection by reduction of oxidative
stress [19]. In our model of PN, however, potent Nrf2 inducer D3T promoted an increase in
oxidative stress under AGE challenge (Fig. 3.5). Under control conditions, treatment with D3T
led to a significant increase in GSH and had no effect on GSSG (Figs. 3.2 & 3.3). Upregulation
of antioxidant enzymes with D3T treatment allows for increased intracellular GSH and
maintenance of glutathione in its reduced form by GR. This scenario reverses in the AGEchallenge group. D3T treatment no longer leads to increased GSH, and there is a dramatic
increase in GSSG compared to the BSA control group. Under AGE conditions, treatment with
D3T promotes further increase in G6PD (Fig. 3.6). By increasing G6PD there is a likely increase
in NADPH generation that can provide reducing equivalents for NADPH oxidase, leading to the
rise in ROS generation that is observed (Fig. 3.5). GSH stores can then be depleted by
antioxidant enzymes such as glutathione peroxidase (Gpx), and GSSG concentrations will begin
to rise. Due to suppression of GR activity, redox balance is no longer maintained, and cell
morphology and viability deteriorate (Fig. 3.14).
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The pathogenesis of PN has been strongly linked with excess production of ROS and the
disruption of the redox state [36], leading to complications such as axonal degeneration [37].
Previously in our laboratory, Pazdro and Burgess quantified loss of neurite number in RA
differentiated SH-SY5Y cells after AGE challenge as a marker of neurite deterioration [22,23].
We expanded on this method, and quantified neurite length and long neurite number. This was
done to observe the effects of antioxidants on protection against neurite retraction and protection
of long neurites upon AGE-challenge. We focused on the long neurites, neurites equal to or
longer than the average neurite length in the control BSA group, because in PN the longest
neurons are generally the first to get damaged [36,37]. AGE-challenged cells showed significant
deterioration of neurite structure, with mean neurite length dropping from 115 to 76 pixels (Fig.
3.11). D3T treatment under AGE-challenge had no further effect, potentially due to a floor effect
where the extent of neurite damage in our model is maximized. However, G6PD inhibition with
DHEA was able to completely rescue neurite length under both AGE and AGE-D3T challenge
(Fig. 3.11). An even more dramatic change was observed with AGE and AGE-D3T challenge on
the average number of long neurites. The BSA control group contained an average of 21 long
neurites per field of view, and this number dropped significantly to 6.8 and 3.3 for AGE and
AGE-D3T groups, respectively (Fig. 3.12). Again, DHEA treatment completely protected
neurites in both groups (Fig. 3.12). These results in differentiated SH-SY5Y cells bring to light
the potentially critical role of G6PD and NADPH in potentiation of AGE-mediated neuronal
degeneration. Strategies aimed at increasing expression of Nrf2 target antioxidant enzymes such
as G6PD may need to be revaluated within the context of AGE-induced PN.
AGE and AGE-D3T-challenge conditions lead to neurite degeneration (Fig. 11&12), and
research in our laboratory is ongoing to establish the mechanism responsible for this effect. Of
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interest is the accumulation of GSSG in stressed conditions. Exogenous application of GSSG in
differentiated NSC34 cells led to tubulin glutathionylation and significant neurite retraction [38].
A similar mechanism may be at play in our cell culture model. The accumulation of GSSG (Fig.
3) may initiate glutathionylation of neurite structural proteins, as GSSG can react with cysteine
residues to form mixed disulfides [39,40]. With depletion of glutathione stores (Fig. 2), activity
of glutaredoxin-1, the major enzyme responsible for reducing mixed disulfides [39], would be
suppressed and glutathionylated proteins would accumulate. Confirming this mechanism in
future studies will be crucial in establishing why maintaining GSH is critical for neurite
protection.
In conclusion, results of this study continue to support previous data from our laboratory
that GSH is critical for maintaining neurites in differentiated SH-SY5Y cells. We show that
under AGE-challenge conditions, D3T further disrupts redox balance and potentiates ROS
generation. This potentiation effect is due to upregulation of the Nrf2 responsive gene G6PD,
and a decrease in the activity of GR. Botanical Nrf2 inducers, such as D3T, are seen as protective
against diseases with an oxidative stress component [36]. However, the results suggest that Nrf2
inducing phytochemicals may exacerbate AGE-mediated neuronal degeneration. Further studies
in different cell lines and animal models will need to be conducted before phytochemicals such
as D3T can be recommended or advised against for patients suffering with diabetic PN.
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Figure 3.1 NAC and D3T treatment increases total GSH.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during BSA and AGE treatment. GSH
concentrations were normalized to total protein. Data were analyzed by two-way ANOVA with
Tukey’s post-hoc analysis from 3 independent experiments. Bars linked with an * are
significantly different (p <0.05).
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Figure 3.2 D3T does not protect reduced GSH under AGE-treated conditions.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during BSA and AGE treatment.
Reduced GSH was calculated by subtracting 2x GSSG from total GSH. Data were analyzed by
two-way ANOVA with Tukey’s post-hoc analysis from 3 independent experiments. Bars linked
with an * are significantly different (p <0.05).
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Figure 3.3 D3T exacerbates AGE-induced GSSG increase.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during BSA and AGE treatment. GSSG
concentrations were normalized to total protein. Data were analyzed by two-way ANOVA with
Tukey’s post-hoc analysis from 3 independent experiments. Bars linked with an * are
significantly different (p <0.05).
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Figure 3.4 D3T exacerbates AGE-induced viability loss.
Differentiated cells were treated with 100 μM D3T for 24 hours prior to 5 mg/mL BSA or AGE
treatment. D3T was replenished during BSA and AGE treatment. Viability was assessed using an
MTT assay and results are presented as values relative to control (BSA) group. Data were
analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 4-5 independent
experiments. Bars with superscript letters different from each other are significantly different (p
< 0.05).
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Figure 3.5 D3T exacerbates AGE-induced ROS generation.
Differentiated cells were treated with 100 μM D3T for 24 hours prior to 5 mg/mL BSA or AGE
treatment. D3T was replenished during BSA and AGE treatment. Data were analyzed by oneway ANOVA with Tukey’s post-hoc analysis from 4-5 independent experiments. Bars with
superscript letters different from each other are significantly different (p < 0.05).
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Figure 3.6 D3T treatment results in increased G6PD protein expression.
Differentiated cells were treated with 100 μM D3T for 24 hours prior to 5 mg/mL BSA or AGE
treatment. D3T was replenished during BSA and AGE treatment. Blots shown are representative
samples of each group. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis
from 3 independent experiments. Bars not linked by a superscript letter are significantly different
from each other (p < 0.05).
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Figure 3.7 Impact of NAC and D3T treatment on GR protein expression.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during BSA and AGE treatment. Blots
shown are representative samples of each group. Data were analyzed by one-way ANOVA with
Tukey’s post-hoc analysis from 3 independent experiments. Bars not linked by a superscript
letter are significantly different from each other (p < 0.05).
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Figure 3.8 D3T treatment reduces GR activity in AGE-challenged cells.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during BSA and AGE treatment.
Results are presented as a % of the control (BSA) group. Data were analyzed by one-way
ANOVA with Tukey’s post-hoc analysis from 3 independent experiments. Bars with superscript
letters different from each other are significantly different (p < 0.05).
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Figure 3.9 DHEA inhibits AGE and D3T-induced ROS generation.
Differentiated cells were treated with 100 μM D3T and/or 100 μM DHEA for 24 hours prior to 5
mg/mL BSA or AGE treatment. D3T and DHEA were replenished during BSA and AGE
treatment. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 3-4
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 3.10 G6PD inhibition protects against AGE and D3T-induced viability loss.
Differentiated cells were treated with 100 μM D3T and/or 100 μM DHEA for 24 hours prior to 5
mg/mL BSA or AGE treatment. D3T and DHEA were replenished during BSA and AGE
treatment. Data were analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 3-4
independent experiments. Bars with superscript letters different from each other are significantly
different (p < 0.05).
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Figure 3.11 DHEA protects against AGE-induced neurite retraction.
Differentiated cells were treated with 100 μM D3T and/or 100 μM DHEA for 24 hours prior to 5
mg/mL BSA or AGE treatment. D3T and DHEA were replenished during BSA and AGE
treatment. A minimum of 100 neurites per group were analyzed. Neurite length in 10x images
was quantified using Image J software with NeuronJ plugin. Data were analyzed by one-way
ANOVA with Dunnett’s post-hoc analysis. Bars with an * are significantly different (p < 0.05)
compared to control (BSA).
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Figure 3.12 DHEA protects against AGE-induced loss of long neurites.
Differentiated cells were treated with 100 μM D3T and/or 100 μM DHEA for 24 hours prior to 5
mg/mL BSA or AGE treatment. D3T and DHEA were replenished during BSA and AGE
treatment. A minimum of 100 neurites per group were analyzed. Long neurite number in 10x
images was quantified using Image J software with NeuronJ plugin. Data were analyzed by oneway ANOVA with Dunnett’s post-hoc analysis. Bars with an * are significantly different (p <
0.05) compared to control (BSA).
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Figure 3.13 DHEA protects against AGE-induced loss of long neurites and retraction.
Differentiated cells were treated with 100 μM D3T and/or 100 μM DHEA for 24 hours prior to 5
mg/mL BSA or AGE treatment. D3T and DHEA were replenished during BSA and AGE
treatment. Representative 10x images of those quantified using Image J software with NeuronJ
plugin.
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Figure 3.14 Mechanism of the D3T paradox.
Receptor for advanced glycation end products (RAGE); advanced glycation end product (AGE);
NADPH oxidase (NOX); glucose-6-phosphate dehydrogenase (G6PD); glucose-6-phosphate
(G6P); 6-phosphogluconate (6-PGA); glutathione reductase (GR); glutathione peroxidase (GPX);
superoxide dismutase (SOD); antioxidant response element (ARE); nuclear factor (erythroidderived 2)-like 2 (Nrf2); 3H-1,2-dithiole-3-thione (D3T). AGE-challenge results in activation of
RAGE, downstream activation of NOX, and generation of superoxide. Superoxide enters the
cells and undergoes dismutation to hydrogen peroxide. Hydrogen peroxide is reduced to water
and molecular oxygen at the expense of GSH by GPX. These conditions result in the observed
increase in GSSG and decrease in GSH. Addition of D3T further exacerbates this condition by
upregulation of G6PD, leading to increased production of reducing equivalents (NADPH) that
are then used by NOX to generate more superoxide. Furthermore, D3T blunts upregulation of
GR activity, which leads to depletion of GSH, promotes build-up of GSSG, and disrupts redox
balance.
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EFFECT OF DISRUPTING THE THIOL REDOX STATE
ON NEURITE DEGENERATION

4.1

Abstract
Peripheral neuropathy is one of the most common health complications in diabetic patients

with a significant impact on quality of life. Oxidative stress plays a major role in the
development of diabetic peripheral neuropathy, therefore reducing or increasing protection
against oxidative stress should be a key focus for ameliorating diabetic complications. In our
laboratory we use differentiated SH-SY5Y cells as a model system to study the mechanisms of
oxidative stress mediated cell damage and antioxidant protection in diabetic peripheral
neuropathy. Previously, we have shown that disruption of the thiol redox state results in loss of
cell viability and the dying-back (degeneration) of neurites. Treatment with N-acetylcysteine
(NAC), a common antioxidant, protected intracellular glutathione levels and conferred protection
against neurite retraction under pro-oxidative conditions. In the present studies, the effects of
glutathione-mediated oxidative damage were investigated. Exogenous treatment of differentiated
SH-SY5Y cells resulted in significant neurite degeneration. Further disruption of the thiol redox
state via inhibition of glutathione reductase and glutaredoxin-1 exacerbated neurite damage,
resulting in a dramatic increase of thinning neurites and a loss of long neurites. The significant
impact observed of glutathione reductase and glutaredoxin-1 inhibition suggested protein
glutathionylation of structural proteins as a mechanism for neurite degeneration. Treating SHSY5Y cells with advanced glycation end products (AGE) to mimic diabetic conditions resulted
in significant protein glutathionylation. NAC treatment conferred complete protection against
AGE-induced protein glutathionylation. Future studies using glutaredoxin-1 knockdown cells
will need to be conducted to elucidate the role of glutathionylation in neurite degeneration.
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Establishing mechanisms for neurite degeneration has the potential to help with the development
of a targeted approach to protect peripheral neurons of diabetic patients.

4.2

Introduction
Peripheral neuropathy (PN) is one of the most common health complications in diabetic

patients, affecting up to 66% of type 1 diabetics and 59% of type 2 diabetics [1]. Oxidative stress
is implicated as a major contributor to development of diabetes-induced PN [2]. The diabetic
condition results in increased non-enzymatic glycation of proteins, known as advanced glycation
end products (AGE) [3]. Increases in hemoglobin A1c, an AGE, are commonly used as a
diagnostic criterion for both prediabetes and diabetes [3]. In the diabetic state, AGEs accumulate
in peripheral nerves [4] which can lead to binding to the receptor for advanced glycation end
products (RAGE) that is localized in the axons of peripheral neurons [5]. Binding of RAGE
results in increased oxidative stress via downstream activation of NADPH oxidase in a PKCδdependent manner [6,7]. In our laboratory, we use differentiated SH-SY5Y cells stressed with
AGEs as a model of diabetic PN [8,9]. In chapter 3 of this dissertation we show that cells
stressed with AGEs experience increased oxidative stress, as evidenced by increased reactive
oxygen species (ROS) generation, as well as disruption in the thiol redox state, as evidenced by a
decrease in reduced glutathione (GSH) and an increase in oxidized glutathione (GSSG).
Furthermore, AGE treatment resulted in loss of viability and the dying-back (retraction or
degeneration) of neurites. We focused on two dietary compounds with antioxidant properties,
3H-1,2-dithiole-3-thione (D3T), and N-acetylcysteine (NAC), as potential protective agents
against AGE-induced damage.
Initial studies from our laboratory linked neurite protection with maintenance of GSH
[8,9]. Both α-tocopherol and D3T did not confer protection against AGE-induced neurite loss,
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and neither of these antioxidants protected against AGE-induced GSH depletion [8,9]. In fact, in
chapter 3 we show that D3T paradoxically exacerbates AGE-induced viability loss, generation of
ROS, and increased GSSG concentrations. For a full review of the D3T paradox, please see
chapter 3. In summary, D3T treatment in the presence of AGE led to further disruption of redox
balance by inhibition of glutathione reductase (GR) activity and increased ROS generation via
upregulation of glucose-6-phosphate dehydrogenase (G6PD). On the other hand, NAC treatment
was able to maintain GSH in AGE-treated cells and conferred complete protection against AGEinduced damage. These results clearly implicate the critical role that GSH plays in neurite
maintenance and health under stressed conditions. Our results from chapter 2 further implicate
the importance of GSH under baseline conditions, as simple inhibition of GSH synthesis resulted
in neurite retraction.
Our previous studies suggest that glutathione-mediated oxidative damage could be
responsible for the neurite retraction observed in AGE-challenged cells. Peripheral nerves have
low GSH concentrations [10] and diabetes leads to high ROS levels in the axons [11]. PN often
presents as axonal degeneration, where degeneration occurs in a distal-to-proximal manner but
does not induce apoptosis of the parent cell body [1,11,12]. A potential explanation for this
phenomenon could be that axons themselves have a much lower GSH content compared to the
parent cell body [13]. GSSG accumulation in neuronal cells has been shown to induce oxidation
of neurite cytoskeleton proteins such as tubulin, resulting in neurite damage and retraction [13].
In our present studies, the role of glutathione and the disruption of the thiol redox state are
investigated in relation to the potential role they play in neurite degeneration.
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4.3
4.3.1

Methods
Materials
Dulbecco’s Modified Medium (DMEM), Ham’s F12 Medium, penicillin-streptomycin,

and fetal bovine serum (FBS) were purchased from Invitrogen (Waltham, MO). All standard cell
culture flasks and plates were purchased from ThermoFisher Scientific (Waltham, MO). All
reagents such as retinoic acid, bovine serum albumin (BSA), NAC, D3T, and 2-acetylamino-3[4-(2-acetylamino-2-carboxyethylsulfanylthiocarbonylamino)phenylthiocarbamoylsulfanyl]
propionic acid (AAPA) were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise
stated. Oxidized glutathione methyl ester (GSSGme) was purchased from Peptide International
(Louisville, KY).
4.3.2

Cell Culture
SH-SY5Y cells were purchased from ATCC (Manassas, VA) and were cultured initially

in growth media (DMEM, 10% FBS, 1% penicillin-streptomycin, 8 mM glucose) in 6-well plates
(9 cm2) at a concentration of .4 x 106 for 24 hours to allow for adherence. Following adherence,
growth media was replaced with differentiating media (1:1 DMEM: F12, 1% FBS, 8 mM
glucose, 10 μM retinoic acid) for five days to allow for neuronal cell phenotype development.
Treatments for all experiments took place following the five-day differentiation period. Cells
treated with NAC or D3T had 1 mM NAC (<1% PBS) or 100 μM D3T (<1% DMSO) added to
the media 24 hours prior to 5 mg/mL BSA or AGE treatment. This treatment was then
replenished in BSA and AGE treatment groups for 24 hours. For GSSGme, AAPA, or
GSSGme/AAPA combination treated cells, 200 μM GSSGme (<1% DMSO + PBS), 15 μM
AAPA (<1% DMSO + PBS), or 200 μM GSSGme and 15 μM AAPA (<1% DMSO + PBS),
respectively, was added to cells after the differentiation process.
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4.3.3

Lentiviral Transduction
Low passage number SH-SY5Y cells were plated in 12 well plates (4 cm 2) at a density of

1 x 10 5 for 24 hours in growth media to allow for adherence. To calculate total transducing units
needed, a multiplicity of infection of 10 was used. Total transducing units is calculated my
multiplying the total number of cells per well by the desired multiplicity of infection. To increase
cellular uptake of the virus, hexadimethrine bromide (polybrene) was used. SH-SY5Y cells are
sensitive to polybrene, and concentrations above 4 μg/mL result in rapid viability loss. Lentiviral
particles for stable knockdown of glutaredoxin-1 (GRX-1) as well as scramble control were
obtained from Origene (Rockville, MD). Lentiviral particles also contained genes for green
fluorescence protein and puromycin resistance. After adherence, cells were treated with the
appropriate amount of total transducing units and 4 μg/mL polybrene for 20 hours. After
lentiviral treatment, media was replaced with growth media containing no penicillinstreptomycin for 48 hours to allow for cells to recover. Following recovery, cells were split 1:5
in a new 12 well plate and allowed to adhere over a 24-hour period in penicillin-streptomycin
free growth media. Next, media was replaced with .2μg/mL puromycin containing penicillinstreptomycin free growth media. After 3 days, the concentration of puromycin was increased
to .5 μg/mL and then media with this concentration of puromycin was replaced every 3 days for
an 18-day period (total of 21 days of puromycin treatment). After 21 days, a ≥ 90% transduction
rate was achieved as noted by cells expressing green fluorescence.
4.3.4

Preparation of AGE-BSA and BSA Control
AGE-BSA was prepared as was previously reported in our lab [8]. Briefly, 5 mg/ML

BSA in PBS was incubated with 33 mM glycolaldehyde dimer for 20 hours at 37°C. Control
BSA was treated in the same manner, but without the addition of glycolaldehyde. Both control
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and glycated BSA were then concentrated via ammonium sulfate precipitation. Ammonium
sulfate was added to glycated BSA and control solutions (80% ammonium sulfate solution), and
then centrifuged at 10,000g for 30 minutes. Precipitated proteins were resuspended with the
minimal amount of PBS required for resuspension. Solutions were then dialyzed in PBS for three
days, with daily replacement of PBS. Following dialysis, solutions were sterile filtered. The final
concentrations of both glycated and control BSA were approximately 15 mg/mL.
4.3.5

Western Blotting
All Western blots were run using a Mini-PROTEAN Tetra Cell system (Bio-rad,

Hercules, CA). Both 10% and 4-20% gradient polyacrylamide gels were used. Each sample
contained 30 μg of protein. For gel electrophoresis, the running buffer was made up of 25 mM
Tris, 192 mM glycine, and .1% (w/v) SDS at pH 8.3. Gels were run at constant voltage (200v)
for 30-50 minutes. For protein transfer to nitrocellulose membranes, transfer buffer was made up
of 25 mM Tris, .2 M glycine, and 20% methanol at pH 8.5. A constant voltage (90v) for 60
minutes was maintained for transfers. The transfer buffer was refrigerated prior to use, and the
entire apparatus was kept cold (approx. 4°C) during protein transfer. Following transfer, blots
were incubated based on antibody manufacturer recommendations. For GSH, GRX-1, and βactin quantification, blots were incubated for 12 hours on a plate shaker at 4°C with a
monoclonal mouse antibody (1:1000) (Abcam, Cambridge, MA) for GSH, polyclonal rabbit
antibody (1:250) (Abcam, Cambridge, MA) for GRX-1, and monoclonal rabbit (1:1000) (Cell
Signaling, Danvers, MA) for β-actin. Both anti-rabbit and anti-mouse secondary antibodies
(1:1000) were HRP-linked, and an HRP-detection kit followed by photo-development was used
(Cell Signaling, Danvers, MA). GRX-1 bands were normalized to their corresponding β-actin
bands and results reported as % of β-actin.
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4.3.6

Neurite Quantification
At the completion of experiments, photos were taken to document morphological changes

of differentiated SH-SY5Y cells. Images were captured at 10x magnification using a Zeiss Axio
Vert. A1 microscope (Oberkochen, Germany). A Zeiss AxioCam ICm1 camera was used to take
photos using Zeiss Zen2 imaging software. All images were 1388 x 1038 pixels, and exposure
time for all photos was 32.03 ms. Images were then analyzed using ImageJ (NIH) software with
NeuronJ (ImageScience) plugin. Individual neurites were traced, and neurite length was reported
as length in pixels. Neurites that expressed notable thinning across their length were counted in
each treatment group. Neurites present in the field of view were quantified from 6 independent
experiments for each treatment group. Exclusion criteria included counting only neurites with
clearly defined start and end locations. Neurites that were shorter than the width of the cell body
were not counted. For each treatment group, a minimum of 200 total neurites was quantified. To
quantify the impact of treatments on the longest neurites, the number of neurites greater than or
equal to the average length of neurites at time 0 was calculated for each treatment group.
4.3.7

Statistical Methods
Values are presented as group means S.E.M. Treatment effects were tested using a

Student’s t-test for two variables, or analysis of variance (ANOVA) for multiple variables. A
significant ANOVA result was followed by a multiple comparisons of means test (Dunnett or
Tukey HSD), with P<0.05 considered statistically significant.

133
4.4
4.4.1

Results
The Effect of GSSGme Treatment on Cell Morphology
The purpose of this study was to document the role of GSSG in the dying-back

(retraction) of neurites when SH-SY5Y cells are exposed to pro-oxidative conditions. In order to
evaluate the impact of GSSG on cell morphology, 200 μM GSSGme was added to the media for
a period of 40 minutes. Photos of the cells were taken at 10x before and after treatment. 40minute treatment with GSSGme induced significant neurite retraction, resulting in a 19% overall
decrease in neurite length (Fig. 4.1). A visual representation of this retraction process is shown in
Figure 4.2, where the blue arrows point to notable morphological changes over the 40-minute
treatment. GSSGme treatment, however, did not significantly impact the average number of long
neurites (Fig. 4.3) or neurite thinning (Fig. 4.4).
4.4.2

The Effect of AAPA Treatment on Cell Morphology
AAPA is a potent and irreversible inhibitor of both GR [14,15] and GRX-1 [16], and as

such should significantly disrupt the thiol redox state. Treatment of differentiated cells with
concentrations of AAPA above 15 μM induced significant lethality after 40 minutes. 15 μM
AAPA treatment induced significant neurite retraction resulting in a 20% decrease in average
neurite length (Fig. 4.5). Furthermore, AAPA had a dramatic impact on long neurites, leading to
a 63% loss of long neurites in only 40 minutes of treatment (Fig. 4.6). In addition to neurite
retraction, AAPA treatment resulted in a 3.3-fold increase in neurite breakdown (measured as
neurite thinning) (Fig. 4.4). A 10x image of AAPA treated cells is shown in Figure 4.7, with blue
arrows pointing to locations of neurite thinning.
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4.4.3

The Effect of GSSGme and AAPA Combination on Cell Morphology
With AAPA inhibition of GR and GRX-1, addition of GSSGme was expected to further

disrupt the thiol redox state. The combination treatment (200 μM GSSGme and 15 μM AAPA)
for 40 minutes induced significant neurite retraction, resulting in a 29% decrease in average
neurite length (Fig. 4.8). The 40-minute combination treatment also resulted in a 77% loss of
long neurites (Fig. 4.9) and a 4-fold increase in the number of thinning neurites (Fig. 4.4).
4.4.4

The effect of AGE Treatment and Antioxidant Protection on Glutathionylation
Disruption of the thiol redox state and a buildup of intracellular GSSG can result in

increased glutathionylation. Protein glutathionylation was measured via Western blot run under
non-reducing conditions followed by incubation with an anti-GSH antibody. A weak band was
detected in BSA treated cells with a molecular weight of approximately 55 kDa. AGE treated
cells had a 2.6-fold higher intensity band at this molecular weight compared to control BSA
cells. (Fig. 4.10). D3T treatment conferred no protection against AGE-induced glutathionylation
(Fig. 4.10). However, treatment with NAC resulted in complete protection against AGE-induced
glutathionylation.
4.4.5

Generation of Stable GRX-1 Knockdown SH-SY5Y Cells
To establish the role of GRX-1 in neurite protection, particularly under pro-oxidative

conditions, GRX-1 knockdown was attempted via lentiviral transduction. Four unique targetspecific shRNA containing lentiviral particles were used (TL312745VA, TL312745VB,
TL312745VC, TL312745VD) along with a scramble control. Cell transduction efficiency,
measured by cells expressing green fluoresce protein, was estimated to be ≥ 90%. GRX-1
knockdown, as measured by GRX-1 protein expression, was not successful for any of the
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lentiviral variants (data not shown). A combination of all variants was attempted, but also proved
unsuccessful (Fig. 4.11).

4.5

Discussion
A common pathophysiology of PN is the dying-back of neurons in a distal-proximal

manner resulting in axonal degeneration [1]. In diabetic PN, neuronal cells undergo
morphological changes and axonal degeneration but not cellular loss [11,17–21]. In rat dorsal
root ganglia (DRG) cultures, neurons from STZ-diabetic rats showed significant accumulation of
ROS in axons compared to non-diabetic controls [11]. Furthermore, 1-month treatment of
diabetic rats with insulin did not protect against ROS buildup in peripheral neurons. In DRG
cultures from diabetic rats, insulin treatment had no impact on the development of neurite
degeneration [11]. Peripheral neurons can be particularly susceptible to hyperglycemia induced
ROS generation due to expression of GLUT1 [22], which is not responsive to insulin, and overall
low GSH concentrations [10].
Low levels of GSH coupled with increased axonal ROS generation can result in increased
axonal structural protein modifications, such as glutathionylation [13]. As we have shown in
chapter 3, stressed conditions result in an increase of GSSG concentrations. GSSG can react with
free thiols on proteins to form a mixed disulfide (protein S-glutathionylation) via thiol/disulfide
exchange reaction [23]. Glutathionylation can serve a protective role, as it is reversible and can
protect proteins from irreversible oxidative damage. However, when redox balance becomes
disrupted, particularly with depletion of GSH, the antioxidant systems responsible for
maintaining reduced thiols (protein disulphide isomerase, thioredoxin, glutaredoxin) are no
longer effective and proteins remain in their potentially inactive state [23–26]. Glutaredoxins are
the major enzymes responsible for the reduction of glutathionylated proteins, as thioredoxins
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show little to no activity with mixed disulfides [26]. Glutaredoxins are highly dependent on GSH
levels, as they become glutathionylated upon reduction of mixed disulfides and are maintained in
their reduced state by GSH [24,26].
In our study, we added exogenous membrane permeable GSSG (GSSGme) to
differentiated SH-SY5Y cells for 40 minutes to disrupt redox balance and observe and quantify
the effects on axons. As expected, GSSGme treatment led to a significant 19% decrease in
neurite length. Average number of long neurites was also measured, as PN often presents in a
“stocking- glove” distribution, where the longest neurons are damaged first and lead to sensory
and motor nerve dysfunction in the extremities [27,28]. GSSGme treatment did not have a
statistically significant effect on the number of long neurites and thinning neurites. These results
suggested that when cells were stressed with GSSGme, the endogenous antioxidant defense
system was still robust enough to confer protection. GR was of particular interest, as activity of
this enzyme is critical for maintaining the thiol redox state due to its function of reducing GSSG
to GSH [14]. To inhibit GR, differentiated cells were incubated with AAPA for 40 minutes.
However, AAPA is not a specific inhibitor of GR (Ki 56μM, kinact .1 min-1) [14] and also inhibits
GRX-1 (Ki 91.3μM, kinact .127 min-1) [16]. Human GRX-1 catalyzes the reduction of mixed
disulfides and can therefore restore the structure/function of glutathionylated proteins [24].
Treatment with AAPA led to a dramatic decrease in long neurites (63% loss) and a 3.3-fold
increase in neurite thinning. Combination treatment with AAPA and GSSGme resulted in 77%
decrease in long neurites and 4-fold increase in the number of thinning neurites. The significant
impact of GR and GRX-1 inhibition on neurite morphology suggests that disruption in the thiol
redox state plays a critical role in neurite degeneration. Tubulin, a major cytoskeletal protein that
makes up microtubules, is a likely target for glutathionylation due to 20 free thiol groups [13,29].
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Tubulin cysteine oxidation has been shown to interfere with tubulin polymerization [13,30,31],
and equilibrium between polymerized and depolymerized tubulin is essential for microtubule
function and axon structure [13].
In chapter 3 of this dissertation, it was established that maintenance of GSH under
stressed conditions is critical for neurite protection. Depletion of GSH and/or decreased activity
of GR would promote protein glutathionylation [15], inactivation of GRX-1 [26], and induce
neurite retraction [8,9]. We hypothesized that by maintaining GSH, NAC conferred protection
against neurite retraction via protection against glutathionylation of neurite structural proteins. In
this study we showed that AGE treatment induces significant glutathionylation of proteins at
around the 55 kDa molecular weight. This could potentially correspond with α/β tubulin [32], but
confirmation would require redox proteomics [33]. D3T treatment, which was not protective
against AGE-induced GSH and neurite degeneration, did not confer protection against AGEinduced glutathionylation. Importantly, NAC treatment conferred complete protection against
AGE-induced glutathionylation. To confirm the role of protein glutathionylation in neurite
retraction, we attempted to knockdown GRX-1 in SH-SY5Y cells. We hypothesized that with
GRX-1 inhibition, NAC would no longer confer protection against AGE-induced neurite
retraction and glutathionylation regardless of cellular GSH status. These experiments would help
establish a mechanism for GSH protection against neurite retraction. Unfortunately, the lentiviral
constructs we used failed to knockdown GRX-1. New lentiviral constructs with modified targetspecific shRNA will need to be developed to generate a stable GRX-1 knockdown SH-SY5Y cell
line.
In conclusion, results from this study suggest that disruption of the thiol redox state plays
a critical role in neurite degeneration. In particular, glutathionylation of structural proteins such
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as tubulin may result in neurite damage and degeneration. We show that when cells are stressed
with AGE, there is a significant increase in glutathionylation. Critically, NAC confers protection
against this observed protein glutathionylation. Future studies using GRX-1 knockdown cells
will need to be conducted to elucidate the role of glutathionylation in neurite degeneration and to
establish the mechanism of GSH protection.
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*

Figure 4.1 GSSGme treatment induces significant neurite retraction.
Following differentiation, cells were treated with 200 μM GSSGme for 40 minutes. Neurite
length in 10x images was quantified before and after treatment using Image J with NeuronJ
plugin. A minimum of 305 neurites per group were analyzed from 6 independent experiments.
Data were analyzed via 2-tailed Student’s t-test. Bars with an * are significantly different (p <
0.05) from the before treatment group.
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Figure 4.2 GSSGme induces neurite retraction.
Following differentiation, cells were treated with 200 μM GSSGme for 40 minutes. Images are
captured at 10x in the same location at both time points. Blue arrows point to neurite outgrowth
areas that diminish or disappear with GSSGme treatment.
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Figure 4.3 GSSGme treatment does not significantly induce loss of long neurites.
Following differentiation, cells were treated with 200 μM GSSGme for 40 minutes. Neurite
length in 10x images was quantified before and after treatment using Image J with NeuronJ
plugin. A minimum of 305 neurites per group were analyzed from 6 independent experiments.
Data were analyzed via 2-tailed Student’s t-test. Bars are not significantly different (p > 0.05)
from each other.
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Figure 4.4 AAPA treatment results in significant neurite thinning.
Following differentiation, cells were treated with 200 μM GSSGme, 15 μM AAPA, or 200 μM
GSSGme + 15 μM AAPA for 40 minutes. Neurite thinning in 10x images was quantified before
and after treatment using Image J with NeuronJ plugin. A minimum of 214 neurites per group
were analyzed from 6 independent experiments. Data were analyzed via 2-tailed Student’s t-test.
Bars with an * are significantly different (p < 0.05) from their respective before treatment group.
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Figure 4.5 AAPA treatment results in significant neurite degeneration.
Following differentiation, cells were treated with 15 μM AAPA for 40 minutes. Neurite length in
10x images was quantified before and after treatment using Image J with NeuronJ plugin. A
minimum of 238 neurites per group were analyzed from 6 independent experiments. Data were
analyzed via 2-tailed Student’s t-test. Bars with an * are significantly different (p < 0.05) from
the before treatment group.
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Figure 4.6 AAPA treatment results in significant loss of long neurites.
Following differentiation, cells were treated with 15 μM AAPA for 40 minutes. Neurite length in
10x images was quantified before and after treatment using Image J with NeuronJ plugin. A
minimum of 238 neurites per group were analyzed from 6 independent experiments. Data were
analyzed via 2-tailed Student’s t-test. Bars with an * are significantly different (p < 0.05) from
the before treatment group.
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Figure 4.7 AAPA treatment results in neurite thinning.
Following differentiation, cells were treated with 15 μM AAPA for 40 minutes. Images are
captured at 10x. Blue arrows point to neurites showing clear signs of thinning after a 40-minute
treatment of AAPA.
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Figure 4.8 GSSGme and AAPA combination treatment results in neurite retraction.
Following differentiation, cells were treated with 200 μM GSSGme + 15 μM AAPA for 40
minutes. Neurite length in 10x images was quantified before and after treatment using Image J
with NeuronJ plugin. A minimum of 214 neurites per group were analyzed from 6 independent
experiments. Data were analyzed via 2-tailed Student’s t-test. Bars with an * are significantly
different (p < 0.05) from the before treatment group.
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Figure 4.9 GSSGme and AAPA combination treatment results in dramatic loss of long neurites.
Following differentiation, cells were treated with 200 μM GSSGme + 15 μM AAPA for 40
minutes. Neurite length in 10x images was quantified before and after treatment using Image J
with NeuronJ plugin. A minimum of 214 neurites per group were analyzed from 6 independent
experiments. Data were analyzed via 2-tailed Student’s t-test. Bars with an * are significantly
different (p < 0.05) from the before treatment group.
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Figure 4.10 NAC treatment confers protection against AGE-induced glutathionylation.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during the 24-hour BSA and AGE
treatment. GSH band appears at a molecular weight of approximately 55 kDa. Data were
analyzed by one-way ANOVA with Tukey’s post-hoc analysis from 3 independent experiments.
Bars not joined by a common superscript letter are significantly different from each other (p <
0.05).
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GRX-1
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Figure 4.11 Lentiviral transduction does not knockdown GRX-1.
Green fluorescence protein (GFP) scramble control cells and GRX-1 knockdown cells expressed
the same amount of GRX-1 protein. GRX-1 band appears at a molecular weight of
approximately 10-12 kDa. Data were analyzed via 2-tailed Student’s t-test from 3 independent
experiments per group. Bars are not significantly different (p > 0.05) from each other.
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SUMMARY AND FUTURE DIRECTIONS

5.1

Summary
Diabetes mellitus is one of the most common chronic diseases and PN affects at least

50% of diabetic patients [1,2]. Medications available to patients ameliorate symptoms (pain), but
do not protect against cellular damage and come with severe side effects leading to discontinued
use [3,4]. The lack of proper available treatment will continue to make PN a major public health
concern, especially because it is estimated that 37% of US adults are currently classified as
“prediabetic” [5]. Patients with prediabetes and metabolic syndrome are also at elevated risk for
development of PN [2]. After development of PN, reversal is very difficult. Therefore, treatment
and prevention strategies should also be focused on groups most susceptible to the development
of PN. The most effective treatment or prevention strategy for PN is a return to normoglycemia
[6,7]. Many times, however, this requires significant lifestyle modifications that include changes
in both diet and exercise. For diabetic patients, additional comorbidities such as PN make this
task more difficult to achieve. Establishing treatment and prevention strategies for PN should be
of utmost priority. Prevention, slowing onset, or improvement of symptoms of PN can
significantly improve the quality of life of prediabetic and diabetic patients and give them more
tools to make difficult and dramatic lifestyle changes to combat diabetes.
Because oxidative stress is implicated as a major contributor to the development of
diabetic PN [8], this dissertation focused on two easily assessible dietary compounds with
antioxidant properties. In chapter 2 of this dissertation N-acetylcysteine (NAC), a thiolcontaining compound known for its potent antioxidant properties, was studied. Differentiated
SH-SY5Y cells were used as a model for peripheral neurons. In this cell culture model, diabetic
conditions and the resulting induction of oxidative stress were mimicked by incubating cells with
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advanced glycation end products (AGE). AGE treatment resulted in significant neurite
degeneration, which was quantified by measuring neurite length and neurite number. The current
studies confirmed previous results that NAC conferred complete protection against AGE-induced
neurite degeneration. Because NAC can confer protection either as a free radical scavenger
and/or through maintenance of glutathione, the mechanism of NAC protection was explored.
Establishing this mechanism was of high importance, as the free radical scavenging properties of
NAC are not observed in in vivo studies due to low bioavailability of native NAC due to
metabolism [9,10]. By inhibiting glutathione synthesis, it was established that NAC conferred
protection against AGE-induced neurite degeneration via a glutathione-mediated mechanism.
With glutathione synthesis inhibited, NAC lost all protective effects. These studies further
established the critical role of glutathione in neurite protection and maintenance. Inhibition of
glutathione synthesis in differentiated SH-SY5Y cells under control conditions resulted in
neurite degeneration quantified by a decrease in average neurite length and loss of long neurites.
Chapter 3 of this dissertation focused on 3H-1,2-dithole-3-thione (D3T), a
compound/phytochemical found in cruciferous vegetables that generates its antioxidant effect
through stimulating endogenous cellular antioxidant defenses. As a potent nuclear factor
(erythroid-derived 2)- like (Nrf2) inducer, D3T was expected to confer protection against AGEinduced neurite degeneration. Paradoxically, D3T appeared to exacerbate AGE-induced damage
[11]. In the present studies, D3T treatment exacerbated AGE-induced buildup of oxidized
glutathione, further decreased cell viability, increased reactive oxygen species (ROS) generation,
and conferred no neurite protection. D3T treatment increased glucose-6-phospahte
dehydrogenase (G6PD) protein expression, a Nrf2 responsive gene. Inhibition of G6PD
completely protected against AGE and AGE-D3T induced damage, suggesting its role as an
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NADPH generating agent may promote oxidative stress rather than provide protection. This
problem was compounded by another important discovery that when cells were stressed with
AGE, D3T treatment reduced glutathione reductase activity. These results explained how D3T
treatment further exacerbated AGE-induced glutathione buildup. In this manner, D3T inhibited
the effectiveness of the endogenous antioxidant defense system and led to disruption of the thiol
redox state. Results from chapter 3 suggest that using a strategy to protect against oxidative
stress by upregulation of the endogenous antioxidant defense system via Nrf2 may backfire and
promote further damage if the products of upregulation contribute to ROS generation.
Results from both chapter 2 and chapter 3 have shown that disruption in the redox state,
as measured by the amount of reduced and oxidized glutathione, leads to neurite degeneration. In
chapter 4, the effects of glutathione-mediated oxidative damage were investigated. Cells treated
with AGEs experienced a significant loss of reduced glutathione and an increase in oxidized
glutathione. This condition can result in a disruption of the thiol redox state, as oxidized
glutathione reacts with free thiols on proteins and forms mixed disulfides (protein
glutathionylation) [12]. Protein glutathionylation is reversible, but reversal is dependent on
reduced glutathione dependent enzyme glutaredoxin-1 [13]. When exogenous membrane
permeable oxidized glutathione (GSSGme) was added to the media of differentiated SH-SY5Y
cells, significant neurite retraction was observed. Further disruption of the thiol redox state via
inhibition of glutathione reductase and glutaredoxin-1 exacerbated neurite damage, resulting in a
dramatic increase of thinning neurites and a loss of long neurites. The significant impact
observed of glutathione reductase and glutaredoxin-1 inhibition suggested protein
glutathionylation (potentially structural proteins such as tubulin) as a mechanism for neurite
degeneration. Treating SH-SY5Y cells with AGEs to mimic diabetic conditions resulted in
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significant protein glutathionylation. NAC treatment conferred complete protection against
AGE-induced protein glutathionylation. Taken together the results show that maintenance of the
thiol redox state is critical for maintaining neurite morphology, and antioxidants such as NAC
that protect the thiol redox state will confer neurite protection in pro-oxidative conditions.

5.2

Future Directions

1. Establishing GRX-1 stable knockdown SH-SY5Y cells
Currently there is no known specific chemical inhibitor for GRX-1. 2-acetylamino-3-[4(2-acetylamino-2-carboxyethylsulfanylthiocarbonylamino)phenylthiocarbamoylsulfanyl]
propionic acid (AAPA) was used in our studies to inhibit both glutathione reductase and GRX-1
[14,15]. In our cell culture model of diabetic peripheral neuropathy, diabetic conditions and
induction of oxidative stress in cells was mimicked with AGEs. The observed increase in
oxidative stress results in a loss of reduced glutathione (GSH) and an increase in oxidized
glutathione (GSSG). When the GSH:GSSG ratio decreases, it can disrupt the thiol redox state of
the cell [16]. One potential outcome of this disruption is the increase in protein glutathionylation.
In chapter 4, it is shown that there is a significant increase in protein glutathionylation when cells
are stressed with AGEs. We show evidence that NAC, which confers complete protection against
AGE-induced neurite degeneration, protects against the observed increase in glutathionylation. It
was hypothesized that NAC would confer protection by maintaining cellular GSH, which would
allow GRX-1 to reduce glutathionylated proteins and prevent neurite degeneration. However,
this question cannot be answered using AAPA as an inhibitor of GRX-1. By inhibiting
glutathione reductase, we are also disrupting other components of the endogenous antioxidant
defense system that are dependent on GSH. Generation of a stable GRX-1 knockdown model, as
was attempted in chapter 4, would allow us to establish the role of GRX-1 in neurite
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maintenance. It was hypothesized that when GRX-1 is knocked down, NAC would no longer
confer protection against neurite degeneration because the cell would not be able to reduce
glutathionylated proteins.

2. Identifying glutathionylated proteins
In the present studies, we were able to quantify the total amount of glutathionylated
proteins by running a Western blot under non-reducing conditions and then using an anti-GSH
antibody. A major glutathionylated protein band appears at a molecular weight of approximately
55 kDa. It was hypothesized that this band could be the microtubule associated structural
proteins α/β-tubulin. Studies done using differentiated NSC34 cells suggest tubulin
glutathionylation could be driving neurite degeneration [17]. To identify the glutathionylated
proteins conclusively, redox proteomics would need to be conducted as done by the Fratelli et al
group [18]. Another protein of interest with a molecular weight matching our GSH band would
be glutathione reductase. In chapter 3 it was shown that the combination of AGE and D3T
treatment led to a significant decrease in glutathione reductase activity. There is a possibility that
the loss of activity was due to glutathionylation of glutathione reductase.

3. Explanation of the glutathione reductase paradox
From our studies in chapter 3, a mechanism for how the potent Nrf2 inducer D3T
exacerbated AGE-induced damage was developed. However, Nrf2 upregulation is an expected
protective response to increased oxidative stress, and D3T is generally regarded as a protective
antioxidant compound [19–22]. In our model system, D3T treatment induced an increase in
G6PD protein expression. The increase of reducing equivalents (NADPH) would be expected to
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confer protection, as glutathione reductase reduces GSSG to GSH in a NADPH-dependent
manner. However, NADPH oxidases are also dependent on NADPH to generate superoxide.
With the observed decrease in glutathione reductase activity, it is possible that increased
NADPH generation via G6PD resulted in increased NADPH oxidase activity in AGE treated
cells resulting in a pro-oxidative condition. Therefore, it is critical to understand the mechanism
behind D3T inhibition of glutathione reductase activity. Preliminary data from our lab suggest
protein carbonyl formation (irreversible protein oxidation) may play a role in glutathione
reductase inhibition (data not shown).

4. Translation of results from SH-SY5Y cells to other models
As a transition step to future application of these results to humans, an intermediate step
would involve animal studies. Prior to designing an animal study, testing other cellular models is
warranted. Translation of the results presented here to a model in primary culture is important to
show the results are not confined to differentiated SH-SY5Y cells. Isolated rat dorsal root
ganglia sensory neurons (DRG) would be a good primary culture model. Rat DRG have been
shown to express the receptor for advanced glycation end products (RAGE) and respond to
RAGE ligand S100 [23]. Use of S100 in DRG resulted in a significant increase of ROS and
neuronal injury [23]. Importantly, DRG isolated from STZ-diabetic rats showed significant
accumulation of ROS in axons and abnormal changes in neuronal outgrowth compared to nondiabetic controls. Furthermore, NAC treatment of STZ-diabetic DRG enhanced neuronal
outgrowth [24]. Important initial experiments to confirm in the rat DRG model would be
evaluation of neurite degeneration and redox balance (GSH and GSSG quantification) in
response to AGE treatment. Follow up experiments would include evaluation of the antioxidants
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NAC and D3T in protection against AGE-induced damage. If D3T treatment exacerbates the
condition as is observed in SH-SY5Y cells, it would be important to test whether other Nrf2
inducers such as diallyl sulfide and sulforaphane have a similar effect [25]. These follow up
studies will need to be conducted (both primary culture and animal studies) before we can
recommend or advise against the use phytochemicals such as D3T in patients suffering with
diabetic peripheral neuropathy. NAC treatment has already been shown to be protective in STZdiabetic DRG [24], but confirmation that protection is conferred via a GSH-mediated mechanism
is necessary. If GSH maintenance is found to be critical for neurite protection, as is the case for
SH-SY5Y cells, future studies should focus on evaluating the neuroprotective properties of both
Nrf2 and non-Nrf2-mediated GSH-inducing substances.
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APPENDIX

BSA

AGE

AGE NAC

AGE D3T

RAGE
β-Actin

Figure A. 1 Treatment does not affect RAGE expression.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during the 24-hour AGE treatment.
Blots shown are representative samples of each group. Data were analyzed by one-way ANOVA
with Dunnett’s post-hoc analysis from 3 independent experiments. Bars with an * are
significantly different from the BSA group (p < 0.05).
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Figure A. 2 NAC protects against AGE-induced protein carbonyl formation whereas D3T does
not.
Differentiated cells were treated with 1 mM NAC or 100 μM D3T for 24 hours prior to 5 mg/mL
BSA or AGE treatment. NAC and D3T were replenished during the 24-hour BSA and AGE
treatments. Western blots of DNPH-modified protein carbonyls shown are representative lane
samples of each group. Data were analyzed via 2-tailed Student’s t-test from 3 independent
experiments. Bars with an * are significantly different (p < 0.05) from the respective BSA
control group.
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Figure A. 3 Differentiated SH-SY5Y cells before treatment.
Neurite length in 10x images was quantified using ImageJ with NeuronJ plugin. Representative
image is shown.
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Figure A. 4 Differentiated SH-SY5Y cells after 40-minute treatment with GSSGme.
Following differentiation, SH-SY5Y cells were treated with 200 μM GSSGme for 40 minutes.
Neurite length in 10x images was quantified using ImageJ with NeuronJ plugin. Representative
image is shown.
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Figure A.5 Differentiated SH-SY5Y cells after 40-minute treatment with AAPA.
Following differentiation, SH-SY5Y cells were treated with 15 μM AAPA for 40 minutes.
Neurite length in 10x images was quantified using ImageJ with NeuronJ plugin. Representative
image is shown.
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Figure A. 6 Differentiated SH-SY5Y cells after 40-minute treatment with GSSGme and AAPA.
Following differentiation, SH-SY5Y cells were treated with 200 μM GSSGme and 15 μM
AAPA for 40 minutes. Neurite length in 10x images was quantified using ImageJ with NeuronJ
plugin. Representative image is shown.

